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Abstract 
Medications are often crushed and mixed with foods or fluids to aid drug delivery for those who 
cannot or prefer not to swallow whole tablets or capsules. Dysphagic patients have the added 
problem of being unable to safely swallow fluids, so thickeners are added to ensure safe 
swallowing. These thickened fluids are then also used to deliver crushed medications in 
replacement of water. This thesis explores the influence of thickened water co-administration on 
drug release in gastric fluid, the effect of rheological properties of these agents and their 
contribution to describing the mechanism of release. The literature review (Chapter 1) examines 
oral dosage form administration, rheological properties of these agents as a means to ensure 
medication delivery and mechanisms of drug release. It is highlighted that thickened fluids have the 
potential to alter drug release but prediction of the effect of co-administration is not currently 
reported.  
Chapter 2 investigates the delivery of medications with thickened fluids as an indicator for potential 
compromise of drug bioavailability. In vitro dissolution in simulated gastric fluid is investigated for 
crushed atenolol immediate release tablets mixed with thickened fluids. Five commercial viscosity-
increasing agents of varied polysaccharide composition are used at three thickness levels prescribed 
for dysphagic patients (levels 150, 400, 900). All types of thickening agents are non-Newtonian 
shear thinning fluids. The greatest thickness (level 900) significantly restricts dissolution, and 
products that are primarily based on xanthan gum also significantly delay dissolution at the 
intermediate thickness level (level 400). The interactions of the polysaccharide chains, particularly 
the rigid rod type conformation of xanthan gum, traps drug molecules within it resulting in impaired 
dissolution. Under the conditions of this experiment, the higher concentrations of thickening agents 
remain in large lumps rather than disintegrating into the media. Drug release is generally affected to 
a greater extent by high-viscosity fluids than low-viscosity fluids at 50 s
-1
, but viscosity at this 
single shear rate of 50 s
-1
 is not a good indicator for effect on drug dissolution because viscosity 
changes with shear rate. The determination of other rheological parameters such as viscoelasticity 
and the effect of breaking up of the structures may be required. 
To investigate whether it is possible to improve drug release from thickened fluids, in Chapter 3 the 
effect of the state of aggregation of the active ingredient with thickened fluids is investigated. 
Paracetamol is the model drug because it is available in a range of formulations with the drug in 
solution (elixir, dissolved effervescent tablet) or dispersion (suspension). Xanthan gum, which 
causes the greatest restriction on dissolution (Chapter 2), is used at level 900 as the thickener. 
 ii 
 
Crushed tablets with thickener are prepared using manual (i.e. the standard method in clinical 
practice) or mechanical mixing. The unthickened elixir and suspension exhibit different dissolution 
profiles (100% and 34% at 30 min, respectively), but once thickened they are very similar (12% and 
14% at 30 min, respectively). The dissolved effervescent tablet has a very similar dissolution profile 
to the crushed tablets once it is thickened to level 900. Incorporation of the crushed tablets with 
thickener using an overhead stirrer causes a significant reduction in dissolution (27% at 30 min) 
compared to manual mixing using a spatula (36%). Thickened products are weak gels with high 
zero-shear viscosity, and the presence of apparent yield stress in combination with high G’ values 
compared to G” (viscoelasticity) impact drug release. The restriction on drug release is not 
influenced by the theoretical state of the drug (dissolved or dispersed), and the approach typically 
used in clinical practice cannot be improved by altering the order of incorporation or mixing 
method. 
Chapter 4 aims to consider the kinetics of drug diffusion through the thickened fluid in the absence 
of hydrodynamic effects. It is hypothesed that drug diffusion decreases as concentration of 
polysaccharide increases within the thickened system, rheology determines drug diffusion and drug 
release increases when the diffusion pathway is reduced. These postulates are studied using a 
vertical diffusion cell, rheology (viscoelasticity) and drug release from various drop sizes of 
thickened water. Diffusion of atenolol, not dissolution, controls the rate of its release from solutions 
of xanthan gum and guar gum and depends on the concentration of the gums in solution which 
relates to the polysaccharide chain entanglement and rheology. After concentration increases to a 
certain level, diffusion coefficient no longer reduces and rheological parameters are not good 
predictors of diffusivity. Reducing droplet size results in an improvement in drug release rate, 
indicating that shear forces within the gastrointestinal tract that cause thickened fluid droplets to 
break up are expected to increase drug release. 
In conclusion (Chapter 5), drug release from thickened water, used to aid delivery of medications, is 
restricted by the polysaccharide structure and break-up forces acting on it. This restriction is drug-
dependent and likely to be affected by tablet excipients, and requires further consideration. Delivery 
of crushed medications in an alternative fluid would be advisable, for example an agent that 
changes its conformation in response to applied forces or the acidic environment that are typical of 
the stomach. Ultimately, assessment of in vivo drug release and absorption from crushed tablets 
delivered in thickened fluids is required for correlation with the in vitro data presented here. 
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1. Chapter 1.  Introduction, rationale and literature review 
1.1 Introduction 
Pharmaceutical active ingredients are combined with excipients to produce efficient, safe and stable 
dosage forms. These are presented to the body through various administration routes, interact with 
the biological environment and eventually the drug leaves the dosage form and becomes available 
for absorption. Any event that prevents the normal course of drug release may affect its 
pharmacological effect.  
Solid oral dosage forms are designed to cover the therapeutic needs of the majority of the 
population. Tablets and capsules are designed for adults to facilitate administration, reduce the cost 
and comply with pharmacological treatment. Liquids are provided for those who require flexibility 
in doses and certain organoleptic conditions for example flavoured syrups, suspensions and elixirs 
for infants. However, while some individuals simply dislike swallowing whole tablets and capsules, 
there are people who are unable to use solid oral dosage forms as a result of poor control of the oral 
cavity (dysphagia). Between 10-40% of individuals (>18yrs) have issues with swallowing their oral 
medications and consequently reduced adherence to therapy.  
Strategies to deal with solid oral dosage forms that cannot be swallowed whole commonly involve 
crushing tablets and opening capsules. The powder is then mixed with fluid foods (e.g. jam, honey, 
yoghurt, apple sauce) or thickened water prescribed in the place of water for individuals with poor 
oral control. As a consequence, changes in the pharmacokinetics may be expected to occur, possibly 
as a result of crushing the dosage form that controls the rate of drug release or from 
incompatibilities with food components. 
Fundamental knowledge of the mechanism that controls the release of drugs incorporated into a 
range of food or thickening agents is limited. The diverse physicochemical properties of the active 
ingredient, along with the excipients and type of food, may affect the release mechanism. In this 
thesis, the release of hydrophilic medications from water thickened with polysaccharide-based 
thickeners is investigated. Viscosity is known to influence drug release into the surrounding media. 
Cellulose polymers, or a standard food meal, added to the dissolution media decreases drug release 
and this has been attributed to the viscosity of the media (Radwan et al., 2013). This thesis 
considers the delivery of crushed tablets within structured fluid foods or thickened water, which are 
non-Newtonian shear thinning fluids, and undertakes detailed rheological characterisation in order 
to provide insights into the mechanism of drug release.  
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1.2 Rationale 
The literature review that follows introduces the biopharmaceutical aspects of oral delivery of solid 
dosage forms and problems that occur when patients are unable to swallow their medication due to 
poor control of the oral cavity (dysphagia) or general dislike of swallowing whole tablets and 
capsules. The strategies to overcome swallowing impairment should involve finding alternative 
dosage forms, administration routes, or active ingredients. However, often conventional dosage 
forms are crushed and mixed with fluid foods or thickened fluids to aid swallowing. Thickened 
fluids are prescribed in replacement of water for dysphagic patients to increase viscosity to a level 
where a bolus is created and swallowing can progress safely. For dysphagic patients who are using 
thickened fluids for their water intake, the thickened fluids are also used as a vehicle for crushed 
medicine delivery by patients and health staff in charge of medicine administration. While modified 
release formulations receive attention in terms of recommendations not to crush, there is a 
perception that immediate release tablets can safely be crushed without consequence to patient 
pharmacotherapy. However, there is a potential for thickened water to compromise drug release 
because the gums and starches used in commercial thickening products are used in sustained release 
tablet formulations to delay drug release, and increasing viscosity of dissolution media or stomach 
contents reduces dissolution rate. For medications with a narrow therapeutic index, a reduction or 
delay in drug release may reduce blood levels enough to compromise therapeutic effect.  
The first aim of this thesis (Chapter 2) is to describe the effect of thickeners on release of an 
immediate release tablet. Ideally, immediate release medications should release their contents in the 
stomach and small intestine within a short time frame and crushing and mixing with a vehicle 
should not extend this time frame considerably. A range of commercial thickeners are compared, 
each comprised of different components and used in dysphagia management, using atenolol as the 
model hydrophilic drug. The effect of thickener concentration and viscosity on drug release in a 
dissolution test are investigated. The hypotheses tested in Chapter 2 are: 
 Thickened water at the viscosity levels specified for the management of dysphagia delays drug 
release. 
 Drug release is affected to a greater extent by high-viscosity fluids than low-viscosity fluids at 
50 s
-1
.  
The second aim of this thesis (Chapter 3) is to determine whether the state of drug aggregation (i.e. 
dissolved or dispersed) within the thickened water is an important determinant in its release. The 
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range of commercial paracetamol formulations available (immediate release tablets, effervescent 
tablets, elixir, suspension) allows this investigation. The hypothesis tested in Chapter 3 is: 
 Limitation on drug release is reduced when the drug is dissolved rather than dispersed within 
the thickened water.  
This study takes two approaches to test this hypothesis: firstly by varying the order of adding the 
components to allow the paracetamol to dissolve in water and then mix into thickened water as 
opposed to the standard clinical practice of dispersing crushed tablet powder into pre-thickened 
water. The second approach is to compare the effect on drug release of thickening commercial 
products that have paracetamol dissolved (effervescent tablet, elixir) or dispersed (suspension). 
Additonally, detailed rheological characterisation of the thickened products was carried out to 
consider the contribution of viscoelasticity and yield stress to restriction on drug release. 
The third aim of this thesis (Chapter 4) is to consider the kinetics of drug diffusion in order to 
better understand the mechanism by which drug releases from the thickened fluids. Based on results 
from Chater 2 and Chapter 3, the hypotheses tested in Chapter 4 are: 
 Drug diffusion decreases as concentration of polysaccharide increases within the thickened 
system.  
 Viscoelasticity is a determinant of drug diffusion within the polysaccharide thickened system. 
 Reducing the diffusion pathway, by breaking the thickened fluid mass into multiple smaller 
droplets, increases drug release.  
These hypotheses are tested using vertical diffusion cells to measure the diffusion coefficient of 
atenolol and rheometers to measure viscoelasticity and viscosity for thickened fluids prepared with 
xanthan gum (a charged polysaccharide with non-Newtonian shear thinning behaviour), guar gum 
(an uncharged polysaccharide with non-Newtonian shear thinning behaviour) or maltodextrin (a 
Newtonian fluid).  
In the final chapter of this thesis (Chapter 5) the main conclusions are presented with discussion of 
future directions for this area of research, considered in terms of 1) the polysaccharide thickening 
agent, 2) the drug dosage form and 3) the techniques used for the measurements. 
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1.3 Literature review  
This literature review aims to explore current research on the topic of oral drug delivery in people 
who are unable to swallow whole tablets and capsules. It does this by considering the importance of 
swallow function in oral drug delivery and the causes of swallow dysfunction (dysphagia), and the 
prevalence of problems with swallowing solid dosage forms. Patients and/or their carers may 
modify these dosage forms, i.e. crush tablets or open capsules and mix the powders with products 
that have an appropriate consistency to enable adequate swallowing function. Thickening agents, 
commonly used to aid for delivery of fluids to patients with dysphagia, are considered in terms of 
their rheological attributes, and the limited quantity of literature available that relates to drug release 
from thickened fluids is reviewed. 
1.3.1 Oral drug administration and drug delivery  
Pharmaceutical active ingredients for oral delivery are presented to the body in an adequate physical 
form. The combination of physical and chemical properties such as lipophilicity, solubility in 
gastric fluids, crystallinity (polymorphism) and pKa produces solids, liquids and semisolid forms 
(Figure 1-1). Combination with excipients and pharmaceutical technology produces efficient, safe 
and stable drug products (Mudie et al., 2010). Oral dosage forms must enable the drug to be 
released and reach the absorption site for it to be absorbed and subsequently exert its 
pharmacological action, depending on the dosage form and the interaction with the biological 
environment. Therefore, any event that prevents drug delivery may negatively affect the biological 
action of the drug. 
 
Figure 1-1. Dosage form classification according to the physical state approved for oral 
administration (adapted from FDA, Data standards manual monographs (FDA, 2009) accessed 
February 2015). 
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1.3.1.1 Biopharmaceutical aspects of drug release 
Properties of the dosage forms and administration route define the course by which a medicinal 
agent reaches the site of absorption. Among the routes available, administration through or by use 
of the mouth has been the most convenient and appropriate way for drug products to be absorbed 
through the small intestinal mucosa. From the mouth to the end of gastrointestinal system, drug 
molecules are influenced by the pH of the fluids, enzyme activity or the action of bile salts and/or 
bio transformation into active or inactive molecules. From the mechanics, the motility pattern also 
influences their biopharmaceutical performance, retaining the dosage form or allowing rapid 
transporting along the gastrointestinal tract. While there are a number of well-known effects 
including: non-invasiveness, stability, cost, and favorable for long-term treatment, certain 
conditions negatively affect the normal transit of an oral dosage form. These are limitations in oral 
processing or in the esophageal, gastric and intestinal active functions. 
Conventional immediate release dosage forms (i.e tablets, capsules) should be swallowed by mouth 
and moved along the gastric tube. At the stomach some physicochemical (gastric juices dilution, 
enzymes) and mechanical (disintegration and mixing) events occur. Dissolution of the drug 
contained in the dosage form is a key process occurring in the stomach that also acts as a mixing 
and temporal chamber with negligible absorption. In the small intestine, the main absorptive site for 
drugs, the active ingredient must be dissolved for the initiation of the absorption process followed 
by metabolism, distribution and circulation. 
1.3.1.2 Dissolution of dosage forms 
Dissolution is a process by which a solid leaves its own phase and becomes part of the fluid. In 
vitro dissolution testing has been used to evaluate the performance of dosage forms and assist in the 
assessment of different formulations or events that may occur in vivo. Dissolution testing measures 
the amount of the drug in solution with time under certain specific conditions. This takes into 
account: (i) pharmaceutical drug product characteristics such as particle size, shape and physical 
state of the drug contained and release criteria (immediate or modified), (ii) media which reflect the 
physicochemical environment of the gastrointestinal tract and (iii) equipment or dissolution 
apparatus aimed to represent the mechanical events in the stomach.  
The dissolution and release testing of drug products must be carried out using standardised 
procedures and the choice of apparatus is determined by the dosage form and the release criteria 
(Table 1-1 and Figure 1-2)  
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Table 1-1. Principal dissolution apparatus, officially addressed in the United States Pharmacopoeia 
(USP) and British Pharmacopoeia (BP) for testing of immediate release (IR), conventional release 
(CR), prolonged release (PR) delayed release (DR), and extended release (ER) dosage forms 
(United States Pharmacopoeia 2011, British Pharmacopoeia 2012). 
Apparatus Description  Dosage forms to be tested  
Apparatus 1 Basket apparatus USP: IR  
BP: CR, PR and DR 
Apparatus 2 Paddle apparatus USP: IR, ER  
BP: CR, PR, DR 
Apparatus 3 Reciprocating cylinder 
apparatus  
USP: ER, DR  
BP: CR, PR, DR 
Apparatus 4 Flow-through-cell apparatus USP: IR, ER, DR 
BP: CR, PR, DR 
 
 
Figure 1-2. Schematic of the dissolution apparatus #2 illustrating drug dissolution rate. Taken from 
(Siepmann and Siepmann, 2013). The arrow indicates particles dissolving from the dosage form. 
In vitro-in vivo correlations should account for multiple factors acting on the dosage form. The 
media composition, pH, buffer capacity, osmolality, surface tension, viscosity, temperature and 
hydrodynamics and fluids secreted along gastrointestinal tract such as hydrochloric acid (HCl), 
bicarbonate, enzymes, surfactants, electrolytes, and mucus, as well as volume of the media, may 
affect solubility and dissolution. These are dependent on many conditions including: duration of the 
process, presence of meals (fed and fasted state) or disease condition, volume of secretions, and the 
 7 
total volume (Mudie et al., 2010). The use of a simple media, such as simulated gastric fluid, is a 
typical environment used to simulate the conditions of the fasted state in the gastric environment.  
For the active ingredients contained in drug products, solubility and permeability are the primary 
physicochemical properties of the drug, recognized for the Biopharmaceutical Classification 
Scheme (BCS). According to that classification, understanding the processes of dissolution and 
permeation of a drug may forecast the possible effects on human organisms to validate changes in 
formulations or when the influence of food should be assessed (Amidon et al., 1995). The 
classification stated four categories as follows: 
 Class I: High solubility, high permeability: Generally well absorbed compounds. 
 Class II: Low solubility, high permeability: Exhibit dissolution rate-limited absorption.  
 Class III: High solubility, low permeability: Exhibit permeability rate-limited absorption.  
 Class IV: Low solubility, low permeability: very poor oral bioavailability.  
The biopharmaceutical assessment of formulations implies that a factor such as gastrointestinal 
motility may have an effect on the transit time of the dosage form as well as the mechanical stress 
and media flow. The influence of hydrodynamics on dissolution testing using apparatus 2, for 
example, is complex and varies according to the type of surface and position of the specimen and 
velocity component influenced by the tangential velocities (Healy et al., 2002, Bai et al., 2007, Bai 
and Armenante, 2009, Bai et al., 2011). Dissolution testers generally fail to replicate the fluid 
mechanics present in vivo. In spite of this, dissolution testing provides insights on the main events 
influencing drug release and information on the underlying mechanism under relatively controlled 
conditions, allows systematic variation of the formulation, and enables identification of problems 
with a formulation or the influence of co-administration of fluids different than water. 
The influence of mechanics on the gastric release and absorption could be assessed in a more 
physiologically-relevant environment. A number of attempts to create more realistic representations 
of the gastro-intestinal environment have been made, such as the dynamic gastric model (DGM) 
(Wickham et al., 2009) and the fed stomach model (FSM) that aim to represent the stomach, and the 
TNO gastrointestinal model (TIM-1) that is intended to simulate the physiological conditions of the 
stomach through to the small intestine (Minekus et al., 1999). Non-standard apparatus such as these 
simulate many aspects of the complex dynamics occurring during passage along the gastrointestinal 
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tract and assist in elucidating drug release mechanisms that are critically important for designing 
drug delivery systems and regulatory evaluation and approval. 
1.3.1.3 Oral drug administration 
Swallowing is a complex process by which a solid or liquid bolus is propelled from the mouth to 
the stomach to be digested, which can be divided into four stages (Figure 1-3). It is driven by a 
central pattern generator (CPG) in the central nervous system which transmits the signal to trigger 
swallowing. Swallowing is typically described as having four stages (Ertekin and Aydogdu, 2003, 
Smith, 2008). As a consequence, anything that affects the anatomy or physiology of swallowing 
affects the normal ingestion of food, liquids and medicines. Certainly, swallowing problems are a 
global concern affecting individuals in all age spans. The prevalence of swallowing disorders 
depends on the age group, presence of co-morbidities (i.e, Parkinson, stroke, dementia), severity of 
swallowing disturbance and the criteria to measure it.  
 
Figure 1-3. Schematic of the anatomical structures and physiological function of normal swallowing 
(Smith Hammond, 2008). 
1.3.1.4 Factors affecting swallowing  
 Age group  
For infants, feeding difficulties represent the main problem in swallowing with prevalence figures 
of 25–45% due to structural, neurologic conditions, respiratory compromise, and other medical 
conditions (genetic, metabolic or degenerative diseases) (Mercado-Deane et al., 2001). Swallowing 
ability tends to improve with developmental progression of eating food of various textures and the 
stimulation of the organs and senses to promote adequate function (Miller, 2009, Owen et al., 
2012). Liquid dosage forms are generally provided for children who have not fully developed the 
ability to swallow solid dosage forms or with an aversion to swallowing tablets. Solid oral dosage 
forms can be administered after training (Ghuman et al., 2004, Beck et al., 2005). 
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The progression of changes in the cellular, anatomy, physiology, motor and sensory characteristics 
of the human body produces a natural decline of certain functions such as swallowing function 
(Nilsson et al., 1996). With an estimated increase of 21% in the elderly population (aged 60 years or 
over) by 2050, swallowing problems will continue to increase in importance in population health 
(United Nations, 2013). Therefore, it is necessary to address the consequence of swallowing 
disorders and meet the nutritional/hydration/medicine administration and health requirements.  
 Disease-related conditions  
Dysphagia is a disorder in the normal process of swallowing that occurs as a consequence of 
anatomical, physiological failures or as a consequence of stroke, Parkinson’s disease, head and neck 
traumas, cancer, psychiatric illness (Castell and Castell, 1996). Table 1-2 showed the prevalence of 
dysphagia across population and the affected condition. These disorders are classified principally 
into two types; oropharyngeal dysphagia and oesophageal dysphagia. Oropharyngeal dysphagia 
(Table 1-3) results from deficiencies in the muscles or nerves of the oral cavity and pharynx affect 
the first two phases of swallowing (White et al., 2008).  
Table 1-2. The prevalence of dysphagia across population and disease related conbdition condition 
Cause Prevalence Reference 
Stroke 13-94% (Langdon et al., 2007) 
Dementia 84% (Homer et al., 1994) 
Parkinson’s’ Disease 32% (Walker et al., 2011) 
Cancer of the head and neck 50% (Brodsky et al., 2010) 
Individuals over the age of 65 10-30% (Barczi et al., 2000) 
Premature infants 25-55% (Mercado-Deane et al., 2001) 
Developmental disability 
(e.g. cerebral palsy) 
60% (Del Giudice et al., 1999) 
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Table 1-3. Principal causes of oropharyngeal dysphagia (Castell and Castell, 1996). 
Anatomic Neurologic Muscular 
Zenker’s diverticulum 
cricopharyngeal bar 
Tumour (local) 
Enlarged thyroid 
Osteophyte 
Postcricoid web 
Abscess 
Postradiation 
Stroke 
Polio 
Motor neuron disease 
Myasthenia gravis 
Parkinson’s disease 
Cerebral palsy 
Brain tumour 
Multiple sclerosis 
Polymyositis 
Muscular dystrophies 
Thyroid dysfunction 
Myasthenia gravis 
 Psychological aversions  
Individuals who do not have a problem with swallowing food and drink can still manifest a 
psychological aversion to swallowing solid dosage forms (Hansen et al., 2008). Factors such as the 
type of formulation, size, shape and surface characteristics of medications as well as a patient’s 
body position may impact the method of delivery of medications (Hansen et al., 2008, Chisaka et 
al., 2006). 
 Medication/treatment related issues 
Medications such as drugs for the central nervous system, with neuromuscular and 
immunomodulation effect, medical procedures (i.e radiotherapy) or surgical interventions can 
induce or promote swallowing dysfunction resulting in secondary adverse events, irritation or lesion 
to the mucosa (Worthington et al., 2011). 
1.3.1.5 Prevalence of problems with swallowing solid dosage forms  
Several studies that aimed to identify swallowing difficulties or problems related to dosage form 
administration in specific age groups have been reported (Table 1-4). Overall, it can be inferred that 
10-40% of people (>18 yrs) have issues with swallowing solid dosage forms, with the larger figures 
being from older age groups.  
 11 
Table 1-4. Reports on the prevalence of problems swallowing dosage forms, including the population group and method of assessment 
Study  Population/age group   Method  Prevalence Concluding remarks  
USA 
(Kottke et al., 1990); 
Residents of age care institution 
(>65 yrs) compared with control 
group (30 yrs) 
Questionnaire 40% of 64 age cared resident 
20% of control group 
This study identified problems managing dosage 
forms in the elderly as reported by physicians 
UK 
(Wright, 2002) 
540 self-reported nurses Self-administered 
questionnaire 
15% of nursing home 
residents 
Discuss alternatives to overcome swallowing 
problem and legal implications of these 
practices 
UK  
(Strachan and Greener, 2005) 
792 customers of community 
pharmacies (69-89 yrs) 
Preliminary 
survey 
60% patients experience 
swallowing difficulties 
Participants were identified by pharmacy staff 
as having the potential to have problems 
swallowing tablets 
New Zealand 
(Tordoff, Bagge et al. 2010) 
Patients (75-85 yrs) Interviews  14% respondents  Common practices of taking medicines and 
among them, swallowing problems were 
identified.  
Germany 
(Schiele et al., 2013) 
1051 general practice 
population (18-80 yrs) 
Questionaries’ 
survey  
37.4% prevalence of 
difficulties swallowing solid 
forms  
Odds ratio of 7.9 (p<0.0001) 
Dysphagia/general dislike of medication. 
Identify prevalence by gender/ frequency/nature 
of the problem/ administration habits and 
swallowing causes  
Switzerland 
(Marquis et al., 2013) 
410 respondents from 
community pharmacies  
Prospective with 
semi-structured 
questionnaire  
9%  recurrent problem 
13.4% one past experience 
of solid dosage form  
Underestimation of the swallowing  problems 
from the health professionals and patients did 
not seek medical advice were identified 
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1.3.1.6 Incidence of dosage form modifications  
People unable to swallow standard oral dosage forms may crush or split tablets, or open capsules, 
and incorporate them into fluids or food (Table 1-5). However, this then becomes off-label use of 
the dosage form because approvals for commercial use stipulate that the medicine must be used as 
provided and any changes are not the responsibility of the manufacturer (Griffith, 2003, Griffith, 
2005, Wright, 2002b).  
Table 1-5. Incidence of dosage form modification. 
Objective   Prevalence/institution/ Type of 
modification 
Reference  
To study medication 
administration in 
nursing homes 
61% of staff in nursing home, UK   Crushing or 
opening medication  
(Wright, 2002)  
To identify modified 
medications and 
type of 
modifications in 
hospitals 
79% of 97 health facilities, 
Queensland (Australia) 
Crushing tablets 
and mixing into 
fluid foods or water  
(Nissen et al., 
2009) 
To estimate extent 
of modifications, 
medications and 
methods involved  
34% of 408 observations, medicines 
altered before administration, aged 
care facilities, South Australia, 
(Australia) 
Crushing and 
mixing with fluid 
food  
(Paradiso et al., 
2002) 
To estimate 
incidence of 
crushing of 
medications for 
children  
1227 occasions across 32 health 
institutions 
Crushing tablets 
and capsules and 
mixing with 
sucrose or starch 
for alternative 
delivery 
(Nakamura and 
Ishikawa, 2014) 
Prevalence of 
medicine 
swallowing 
difficulties  
59% of patients with swallowing 
difficulties alter their medications, 
general population   
Not specified (Schiele et al., 
2013) 
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1.3.1.7 Consequences of dosage form modification 
To prescribe medication to those with swallowing issues, prescribers can opt for a different: (i) 
dosage form (ii) administration route (iii) active ingredient (iv) compounded or modified 
formulation and eventually (v) a new delivery system. However, where a change in prescription is 
not possible or desired, impaired patients, parents, caregivers, and health professionals may be 
forced to find their own way to ensure medication delivery. 
Altering solid dosage forms may result in changes in the pharmacokinetic parameters such as the 
rate of drug absorption. Dosage forms designed to deliver the active ingredient over an extended 
period of time with the aim of reducing dosing frequency, or to maintain constant drug levels in the 
blood or tissue, or to delay delivery to a specific organ (i.e. intestine) (FDA, 2009), should not be 
altered as it may change the release pattern and increase the incidence of adverse events (Cleary et 
al., 1999). However, there is a common perception that immediate release formulations can be 
crushed without major concerns regarding dose delivery (Burridge and Deidun, 2011). For instance, 
the administration of crushed and whole voriconazole tablets showed higher drug abruption but 
comparable bioavailability for voriconazole and telithromycin (Dodds Ashley et al., 2007). Other 
reports confirmed increased bioavailability by raising drug plasma levels of clopidrogel and 
pentoxifilin (Zafar et al., 2009, Cleary et al., 1999) resulting in one fatality. Contrary to this, sub-
therapeutic drug levels were due to physical loss during modification of levothryroxine tablets 
which consequently, decreased efficacy with poor management of the health condition (Manessis et 
al., 2008).  
 Mixing with food vehicles 
Crushed medications can be dispersed, sprinkled or mixed with water or other fluid vehicles such as 
apple sauce, jam, custard, yoghurt, honey, juice or thickened fluids (Nissen et al., 2009, Lee et al., 
1996, Gidal et al., 1998, McLean et al., 2001, Fay et al., 2005, Jann et al., 1986, Damle et al., 2002). 
Crushing tablets or opening capsules and mixing with a small quantity (e.g. two tablespoons) of 
food such as pudding, yoghurt or apple sauce usually does not significantly alter bioavailability 
(Lee et al., 1996, Gidal et al., 1998, McLean et al., 2001, Damle et al., 2002). However, certain 
foods are known to affect drug absorption, for example a component in fruit juice such as 
grapefruit, orange and apple juice affects absorption of numerous medicines (Bailey, 2010, Jeon et 
al., 2013, Lilja et al., 2005) and fibre products ingested with the medication affect gastric emptying 
(Damle et al., 2002, Huupponen et al., 1984). Furthermore, mixing crushed phenytoin tablets with 
pudding resulted in impaired absorption in comparison to the use of apple sauce (Jann et al., 1986). 
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Enteric-coated beads of didanosine administered with yoghurt or apple sauce delayed absorption 
(Damle et al., 2002) and coadministration of quinolones with yogurt decreased absorption and 
bioavailability due to formation of insoluble drug-calcium complex (Neuhofel et al., 2002). In 
another study, milk reduced absorption of oseltamivir due to direct interaction with the proton 
coupled oligopeptide transporter (PEPT1) (Morimoto et al., 2011). Consequently, the effects of 
food have to be considered case by case and the practice of mixing drug products into them cannot 
be taken for granted. 
 Mixing with polysaccharide-based thickeners 
According to the severity of the swallowing impairment, patients are prescribed with food and 
drinks modified to have certain physical attributes such as viscosity, modified texture and moistness 
for safe swallowing function. Normal ingestion relies on the manipulation and control in the oral 
cavity (Crary and Groher, 2006, Keller et al., 2012). Where there is poor oral control of propulsion 
of thin fluids and foods, these may be inadvertently transported to the airway which results in 
aspiration, choking and suffocation. Thick fluids are the primary choice for fluid administration as 
they slow bolus transit, providing improved control of oral and pharyngeal movements in a timely 
manner (Dantas et al., 1990), thereby preventing further problems such as aspiration (Garcia and 
Chambers, 2010). 
To prevent the concerns of thin fluids aspiration, water is commonly thickened with viscosity-
increasing agents and used in the place of water to deliver medications. A number of these 
thickening agents are specially formulated while others are supermarket items that may be used to 
thicken fluids and mixers (He et al., 2008). These agents are aqueous fluids containing a single or 
combination of natural biopolymers including xanthan gum, guar gum, carob bean gum, tara gum, 
maltodextrin and modified starch (Nutrition Australia, 2011), which hydrate and swell to eventually 
increase the viscosity of the water.  
1.3.2 Thickening agents used for dysphagia 
Thickening agents must provide correct viscosity, adhesiveness and cohesiveness as well as 
smoothness to facilitate swallowing (Nutrition Australia, 2011). However, the thickness of products 
for use in dysphagia is described using a range of terminologies and there is not currently a uniform 
system used internationally. In Australia, there are three recognised viscosity levels: Level 150, 400 
and 900 which correspond to the viscosity in centipoise measured at a shear rate of 50 s
-1
. These 
approximate to similar systems used in other countries (Table 1-6).  
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Table 1-6. Comparison of food texture and fluid classification system for individuals with 
dysphagia (Dieticians Association of Australia and The Speech Pathology Association of Australia 
Limited, 2007) 
Australia and  
New Zealand 
Ireland UK USA 
Texture modified foods 
Regular   Regular 
Texture A – Soft (1.5cm) Texture A - Soft Texture E – Fork 
Mashable Dysphagia diet 
(1.5cm) 
Dysphagia Advanced 
(‘bite sized’),< 2.5cm  
Texture B – Minced and 
Moist (0.5cm) 
Texture B – Minced and 
Moist 
Texture D – Pre-Mashed 
Dysphagia Diet (0.2cm) 
Dysphagia Mechanically 
altered (0.6cm) 
Texture C – Smooth pureed Texture C – Smooth 
Pureed 
Texture C – Thick Pureé 
Dysphagia Diet 
Dysphagia Puree 
 Texture D - Liquidised Texture B – Thin Pureé 
Dysphagia Diet 
 
Liquids 
Regular  Thin fluid Thin (1-50 cP) 
 Grade 1 – Very mildly 
thick  
Naturally thick fluid  
Level 150 – Mildly thick Grade 2 – Mildly thick  Thickened fluid – Stage 1 Nectar-like thick fluids 
(51-350 cP) 
Level 400 – Moderately 
thick 
Grade 3 – Moderately 
thick  
Thickened fluids – Stage 
2 
Honey-like thick fluids 
(351-1750 cP) 
Level 900 – Extremely 
thick 
Grade 4 – Extremely 
thick 
Thickened fluid – Stage 3  Spoon-thick fluids (> 
1750 cP) 
1.3.2.1 Rheological attributes of thickened fluids  
Rheology is the science of deformation and flow of matter, and involves the study of fluid viscosity, 
defined as the measure of the resistance to flow (Figure 1-4). Fluids that respond with a constant 
viscosity with shear stress or shear rate are Newtonian-type fluids. Examples of Newtonian fluids 
include: water, sugar solutions, and honey. Those fluids with a shear stress that has a nonlinear 
dependence on shear rate are termed non-Newtonian fluids. These can be shear-thinning or shear-
thickening fluids, whereby the apparent viscosity decreases or increases, respectively, with shear 
rate (Coster and Schwarz, 1987, Barnes et al., 1989). Of particular relevance to this research are the 
shear-thinning fluids that are gel-like at low stress and characterised by high zero-shear viscosities 
at low shear rates and low infinite-shear viscosities at high shear rates. Examples of these fluids are 
the biopolymers present in food, beverages and thickening products used to treat swallowing 
disorders. 
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Figure 1-4. Flow curves for typical time-independent fluids taken from taken from (Steffe, 1996). 
Weak gels are also characterised by an apparent yield stress; this is defined as a minimum required 
shear stress to initiate flow of the fluid. If the stress applied overcomes the yield or critical stress 
value, the fluid flows or fractures as a result of the alteration of the internal structure (Stokes and 
Frith, 2008). Yield stress also has implications in swallowing physiology; for instance, in the oral 
stage of swallowing, as the bolus is placed in the oral cavity, the tongue applies a considerable force 
(stress) to the bolus to propel it into the pharynx and past the airway. If this force is not enough (e.g. 
due to the person being unable to produce the stress, or the bolus not responding to the stress by 
flowing) the bolus may be unable to move safely, potentially causing choking or aspiration episodes 
that are dangerous for patients with swallowing impairments (Cichero et al., 2000).  
a) Dynamic oscillatory characterization  
Aqueous polymer solutions and weak gels exhibit rheological characteristics of both elastic solids 
(solid-like behaviour) and viscous liquids (liquid-like behaviour); fluids exhibiting the combination 
of these behaviours are termed viscoelastic (Stokes and Telford, 2004). There are three viscoelastic 
material functions: Linear viscoelasticity, non-linear viscoelasticity and extensional flow (Barnes et 
al., 1989).  
Linear viscoelasticity is the dynamic response of the fluid when stress is linear with strain. This is 
measured using small amplitude oscillatory shear (SAOS), whereby the shearing surface oscillates 
sinusoidally back and forth. The response is measured by two stress components: G’ or the shear 
storage modulus, which oscillates in-phase with the strain and G”or the shear loss modulus, the 
component of the stress 90° out of phase with strain. In the region of linearity, both are examined as 
functions of frequency of oscillation (Stokes, 2012b, Steffe, 1996).  
The frequency sweep test is common technique used to reveal how elastic and viscous components 
in the material change with the rate of application of the stress or strain. At frequencies where G’ > 
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G”, the material is behaving in a solid-like fashion and directly indicates the structure of the 
material (Steffe, 1996). 
b) Instrumentation to measure rheological attributes  
In the health sector subjective assessment of thickeners commonly uses “thin” and “thick” to 
characterize food thickeners used for swallowing disorders (Cichero et al., 2000). This practice does 
not objectively describe the rheology of the fluids and the term viscosity should be used instead. If 
viscosity is expressed as a unique value for comparisons, the shear rate may be defined (Steffe, 
1996), (Stokes, 2012b). Material rheology can be measured using apparatus that vary in design, cost 
and characteristics of the test. These are classified as rotational or capillary type instruments and 
generally used for time-dependent measurements (Steffe, 1996). According to the physical state of 
the sample and the measurement, specific geometry is chosen (Table 1-7).  
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Table 1-7. Summary of tool geometry used to measure the rheology of fluids (adapted from (Barry 
and Meyer, 1979, Steffe, 1996, Barnes et al., 1989, Stokes, 2012b).  
Geometry 
Principle Errors Utility 
Concentric cylinders 
(Bob and cup)  
Fixed plate an outer 
cup with an inner 
cylinder suspended by 
a torsion wire. Narrow 
wall  
End effects 
Wall slip  
Inertia  and secondary 
flows 
Eccentricities  
Not normal stress  
measurements  
Viscous heating  
Useful for viscosities  <  
100 Pas  
Adequate for high shear 
rates  
Less effect on gravity due 
to settling 
Normal stresses difficult to 
measure  
Rod climbing  
Parallel plate  Two parallel plates 
separated a ℎ distance 
in which the fluid is 
confined. Shear rate is 
a function of the 
radius, so shear rate 
varies from zero in the 
middle to a maximum 
at the outside rim    
Inertia and secondary 
flow  
Edge fracture 
Shear heating  
Non-homogeneous strain  
Simplicity on loading the 
sample   
Wall slip can be measured 
at two gaps  
 
Cone and plate  Cone is rotated  
at an angular velocity 
(𝛺) and the torque 
measured  
Shear rate and strain 
do not dependent on 
the radius.  
Direct measure of  
Normal stress.  
Inertia and secondary 
flow 
Torque correction  
Gap opening  
Shear heating  
Inappropriate for 
particulate systems 
Widely used for normal 
stress and for low and high 
viscous systems 
Measurements. 
Homogeneous deformation  
Nonlinear viscoelasticity  
High viscosity limited by 
the edge fracture. Low 
viscosity limited by inertia 
Mixer (Vane ) 
 
The fluid moves as a 
solid plug which 
prevents wall slip  
 Samples with Yield stress  
Rotation in large 
containers 
Large particles can be 
present in the sample 
c) Biopolymer solution rheology  
A range of thickening agents is used to create thickened liquids for treatments of swallowing 
disorders (e.g. xanthan gum, modified maize starch etc). The rheology of a solution containing 
thickening agents depends on its conformation in the solvent (e.g. water), concentration, and 
interaction between polymer chains (Stokes, 2012b).  
The conformation of xanthan gum chains are rigid rod type (Lapasin and Pricl, 1995). In contrast, 
polymer chains of galactomannans (guar gum) are flexible random coil type whose shape 
continually fluctuates (Robinson et al., 1982), while starch is highly branched polymer that forms 
swollen granules (Morris et al., 1981). As a result of differences in structure occuring in a flow field 
(Stokes and Frith, 2008), an individual viscosity value at specific shear rate (i.e 50 s-1) may not 
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entirely characterise flow attributes. Other rheological tests provide detailed information on the 
physicochemical properties of these fluids and the response under an applied stress.  
Concentration of biopolymer determines the interactions of the polymer in solution (Figure 1 5). At 
dilute concentrations, polymer-polymer and solvent-solvent interactions predominate. With 
increasing concentration of biopolymer, the critical concentration c* for entanglement is reached 
which indicates coil overlap and interpenetration of the polymer. Above c*, in the semi-dilute and 
concentrated ranges (Figure 1 5) a network of entanglements is formed (Lapasin and Pricl, 1995) 
  (a)                               (b)               (c) 
 
 
 
Figure 1-5. Polymer concentration regimen (a) dilute, (b) semidilute and (c) concentrated adapted 
from (Masaro and Zhu, 1999). 
Biopolymers obtained from plant seeds, natural plant exudates, marine and microbiological sources 
are broadly used in the pharmaceutical, food and cosmetic industry, and are thus generally 
recognised as safe for human consumption (GRAS). In pharmaceutical formulations, they act as 
diluents, binders, disintegrants and thickeners for oral solutions, and in topical preparations they act 
as protective colloids, suspending agents, gelling agents and are used to form the base of 
suppositories. These polysaccharides constitute the main ingredient in matrix tablets in formulations 
that contain a medicinal agent in combination with hydrophilic or hydrophobic ingredients for a 
sustained drug delivery (Kenyon et al., 1997, Talukdar et al., 1996, Sinha et al., 2004, Nutrition 
Australia, 2011) and depend on the structure of thickening agents. 
1.3.3 Mechanism of drug release 
The mechanism of drug delivery from thickened fluids can be considered in terms of mass transfer. 
The delivery of a molecule at specific time and location is a function of diffusion (molecular 
movement) and convection (mixing) in a dynamic system (Nelson and Shah, 1975). Fick’s laws of 
diffusion were first adopted to provide an insight into the release and traverse of the active 
pharmaceutical molecules through the intestinal wall. This movement, due to the chemical gradient, 
could be described as a flux, 𝐽, Equation 1-1 in which describes Fick’s first law: 
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Equation 1-1 
𝐽 =
𝜕𝑀
𝑆 𝜕𝑡
 
where 𝑀 represents the amount of the material, 𝑡 is the unit time and 𝑆 is the unit area of the barrier. 
Equation 1-2 accounts for the diffusion in the direction opposite to the increasing concentration: 
Equation 1-2 𝐽 = −𝐷
𝜕𝐶
𝜕𝑥
 
where 𝐷 represents the diffusion coefficient and 𝜕𝐶/𝜕𝑥 is the concentration gradient comprised of 
𝐶 which is the concentration and 𝑥 which is the distance. The negative sign in this equation 
indicates that diffusion occurs in the direction of diminishing concentration of the diffusing 
molecules (Crank, 1975).  
Fick’s second law (Equation 1-3) declares that partial change in the concentration with time is 
directly proportional to the partial change in concentration gradient:  
Equation 1-3 
𝜕𝐶
𝜕𝑡
= 𝐷 
𝜕2𝐶
𝜕𝑥2
 
Based on Fick’s second law of diffusion, the theoretical Higuchi model (Higuchi, 1961) describes 
the release of a pharmaceutical active ingredient that is homogenously dispersed in an ointment 
matrix and applied as a thin film (Equation 1-4): 
Equation 1-4 
𝑀𝑡
𝐴
=  √2𝐶𝑖𝑛𝑖𝐷𝐶𝑠𝑡 
where 𝑀𝑡 is the total amount of the drug transferred (mg), 𝐴 is the diffusional transferring area 
(cm
2
), 𝐶𝑖𝑛𝑖 is the initial concentration (mg/mL), 𝐶𝑠 is the concentration solubility (mg/mL), 𝐷 is the 
diffusion coefficient (cm
2
/s) and 𝑡 is the time (s).  
Equation 1-4 can be split into two components to simplify the calculations involved to produce 
Equation 1-5 and Equation 1-6:  
Equation 1-5 
 
𝑀𝑡 = 𝑘√𝑡 
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The model can be described pictorially (Figure 1-6) and assumes the following conditions 
(Siepmann and Peppas, 2011):  
a) Drug transport through the matrix is rate limiting, whereas drug transport after release 
from the matrix is rapid, 
b) There is a perfect sink, 
c) Initial concentration of the drug in the matrix is higher than drug solubility (𝐶𝑖𝑛𝑖 >>𝐶𝑠),  
d) Drug particle size is smaller than the thickness of the matrix, 
e) Drug is homogeneously distributed through the matrix, 
f) Dissolution of the drug particles is rapid compared to the diffusion of the dissolved 
species through the matrix,  
g) The diffusion coefficient of the drug within the matrix is constant and does not depend on 
time or position within the film, 
h) The matrix does not change size (e.g. swell or dissolve) during drug release.  
Equation 1-6 
 
𝑘 = 𝐴√2𝐶𝑖𝑛𝑖𝐷𝐶𝑠 
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Figure 1-6. Schematic of the concentration-distance profile for a drug contained in a thin matrix 
film applied to a surface that provides sink conditions for the drug that diffuses out of the matrix 
(Siepmann and Peppas, 2011). The large rectangle is a cross-section through a film of matrix 
containing dissolved and undissolved drug at a starting concentration 𝐶𝑖𝑛𝑖 . As dissolved drug 
diffuses out of the film, through the membrane and is taken away by the sink conditions on the 
other side of the membrane, the region containing undissolved drug gradually diminishes. At time 𝑡 
the red solid line shows the distance h of the front that separates the part of the matrix closest to the 
sink that contains only dissolved drug (𝐶𝑠) from the part of the matrix that contains dissolved and 
undissolved drug. At time 𝑑𝑡 the front moves (𝑑ℎ) until the remaining solid dissolves and circulates 
through the polymer phase. 
1.3.3.1 Measurement of drug diffusion  
The diffusion cell, also called vertical diffusion or Franz cell, can be used to estimate the diffusion 
coefficient of a drug out of a semi-solid polymer matrix. Natural and modified polysaccharides with 
a GRAS food use status have been studied to evaluate diffusion of released substrates for use as oral 
or topical delivery systems. Issues with reproducibility of this method have been commented on and 
fitting of data collected from diffusion cells to kinetic models was not as good as data collected 
using enhancer cells (Lucero et al., 2013). However, diffusion cells have been useful in the 
estimation of diffusion coefficients for small-sized drugs thorough simple (natural polymers) or 
complex (synthetic) systems (Table 1-8).  
The vertical diffusion cell apparatus used in the present work (Logan Instruments, Somerset, NJ) 
consists of six diffusion cell compartments, each with a donor side (3 mL) and a receptor side (12 
mL) separated by a membrane which has an effective diffusion area of 1.76 cm
2
 (Figure 1-7). 
Moving 
front 
𝑐𝑖𝑛𝑖  
𝑐𝑠  
𝑑ℎ  
Direction of drug release 
Sink 
Distance 
Drug concentration 
ℎ 
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Temperature is thermostatically controlled by a dry heat system (37°C), and centrally controlled 
agitation of 600 rpm for Teflon® cylindrical magnetic bars (10 mm length without ring, one per 
diffusion cell). The receptor side is a vertical glass tube, the top being open to the membrane and 
the base closed by a Teflon stopper, with a lateral flow in and out orifices connected to a sampling 
port that allows sample to be withdrawn and media replaced. The base of the receptor cell remains 
in contact with the agitation sensor from the equipment. 
 
Figure 1-7. Schematic of the vertical diffusion cell apparatus 
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Table 1-8. Drug diffusion studies through polysaccharide systems. 
Drug loaded/polymer Methodology Outcomes References 
Theophylline (Th)  
Hydroxypropyl cellulose (HPC) 
0.2%-2.0% 
Vertical diffusion 
cell (Franz cell) 
Diffusion coefficient decreased exponentially with 
increasing HPC concentration. At 0.8 % HPC, diffusion 
remained constant, indicative of entanglement. 
Microviscosities could potentially predict the resistance of 
a molecule to diffuse. 
 
(Alvarez-Lorenzo et al., 1999) 
Chloramphenicol (Cl) 
Carbopol 934 NF 
Tween 80, Pluronic F-127, 
sodium dodecylsulfate (SDS), 
and benzalkonium chloride 
 
Vertical diffusion 
cell (Franz cell) 
Diffusion of chloramphenicol was unaffected by the 
increase in macroviscosity of carbopol-surfactant system 
but it was influenced by the swelling properties at pH 4 
and 7.4 causing a reduction in diffusion coefficient. 
(Barreiro-Iglesias et al., 2001) 
Theophylline 0-0.4% (Th) 
Scleroglucan 2.0% (Scl) 
Vertical diffusion 
cell (Franz cell) 
Effect of percentage of Th loading 0.04 and 0.06 % w/w 
on the release kinetics and rheology of the gel due to 
plastizing effect reducing scl-scl hydrogen bonds. 
 
(Francois et al., 2005) 
Theophylline (Th) 
Diltiazem (Dz)  
Konjac glucomanan (KGM) 
Xanthan gum (XG) 
Fluorescence 
recovery after 
photobleaching 
(FRAP) 
Source of KGM influenced interactions with XG which 
offers the highest resistance to diffuse. 
Diffusion constants reduced for Dz respect to Th due to 
molecular size and electrostatic attraction Dz and 
negative-charged polysaccharides. 
 
(Alvarez-Mancenido et al., 
2008) 
Theophylline (Th) 
Hydroxypropylcellulose-
methylmetacrylate (HPC-MM) 
Vertical diffusion 
cell (Franz cell) 
vs. 
Enhacer® cell 
Faster diffusion for the systems containing 0.5% w/v of 
theophylline explained by the formation of a relaxed 
structure of HPC-MM, Th, and nonylphenyl ether 
(Lucero et al., 2013) 
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1.3.4 Drug delivery from thickened fluids 
Several reports have addressed the influence of viscosity of the entire dissolution media or stomach 
on drug release and dissolution. Co-administration of drugs with a meal is associated with a higher 
viscosity of stomach contents, which prolongs tablet disintegration time (Parojcic et al., 2008) and 
causes simulated oral absorption to be slower for drugs with limited permeability such as atenolol, 
metformin hydrochloride, furosemide and metoprolol tartrate (Cvijić et al., 2014). After ingestion of 
a meal, water penetration rate decreased resulting in a reduction of diffusivity which reduced 
disintegration and dissolution of trospium tablets (Radwan et al., 2013, Radwan et al., 2014). 
Consequently, as viscosity increases, diffusion decreases and with this there is a reduction in the 
ability to reach the sites of absorption (Fleisher et al., 1999).  
Dissolution rate of benzoic acid tablets was reduced when tested in dissolution media thickened 
using xanthan gum or guar gum (Sarisuta and Parrott, 1982). The presence of dietary fibers in food 
products increases the viscosity of the dissolution media and forms a physical barrier that prevents 
mixing with gastrointestinal fluids (Shono et al., 2009, Abrahamsson et al., 2004, Parojcic et al., 
2008). Furthermore, there is evidence that absorption of whole digoxin, penicillin and metformin 
tablets may be reduced when consumed with guar gum as a source of dietary fibre (Huupponen et 
al., 1984, Gin et al., 1989), and the increased viscosity resulting from guar gum consumption in 
dogs reduced absorption of paracetamol and hydrochlorothiazide by decreasing dissolution rate and 
gastric emptying rate (Reppas et al., 1998). 
Comparatively little attention has been given to the effect of co-administration, i.e. mixing 
medications into a small quantity of thickened water, on drug release. One recent study, poorly 
written and published in a journal of questionable quality, investigated the use of fibroin, a protein 
from silk cocoons, in the preparation of an oral gel formulation of an antispasmodic for elderly 
dysphagic patients (Vijayanand et al., 2012). A 2% gel allowed 90% drug release within the 75 
minute test; viscosity (measured at 50 rpm) increased and drug release reduced as gel concentration 
increased. However, no other rheological properties were measured, and the reported viscosity of 
8000 cps (which is approximately 8 Pas) at 50 rpm is likely to be quite a thin fluid similar to level 
150 (Table 1-6). Two studies specifically aimed to design an oral gel with sustained release 
properties for use by dysphagic patients, using methylcellulose and pectin (Itoh, Hatakeyama et al. 
2011) or carrageenan and agar (Miyazaki, Ishitani et al. 2011). These products were shown to 
restrict paracetamol release, maintain their integrity in the stomach and were considered to be 
suitable for use by dysphagic patients based on gel strength of 2.5-10 kNm
-2
 advised by the 
Ministry of Health, Labour and Welfare in Japan (Miyazaki, Ishitani et al. 2011). However, 
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viscosity was measured at 5°C (Itoh, Hatakeyama et al. 2011) or not at all (Miyazaki, Ishitani et al. 
2011) so comparison with the Australian standards is not possible. Finally, a recent publication 
describes a gel formulation to aid delivery of minitablets to children (Kluk and Sznitowska, 2014). 
The gel was comprised of carboxymethylcellulose and carbopol with sucrose, glycerol, preservative 
and flavouring, and improved swallowing but caused an increase in disintegration time of the 
minitablets. 
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2. Chapter 2.  Investigation of drug delivery from thickening agents to 
aid swallowing of medications 
2.1 Introduction 
The oral route is the most convenient for medication administration. Solid dose forms such as 
tablets, pills or capsules are preferred for the oral delivery of active pharmaceutical ingredients, 
providing accuracy in the dose, maximal storage stability, low cost, as well as patient adherence and 
compliance with the dosage regime. However, medications often cannot be safely administered to a 
patient if the oral route is compromised. 
Anatomical and physiological complications associated with the oral, pharyngeal and esophageal 
phases of swallowing are known as dysphagia (Matsuo and Palmer, 2008). A consequence of 
dysphagia can be aspiration of food, drink or medication leading to risk of airway obstruction or 
pneumonia. Dysphagia is generally associated with other disease-related conditions such as 
Parkinson’s disease, multiple sclerosis, stroke, cancer and dementia and consequently is most 
prevalent in the older population (Cook et al., 1994). Individuals who do not have a problem with 
swallowing food and drink can still manifest a psychological aversion to swallowing solid dosage 
forms (Hansen et al., 2008). Factors such as the type of formulation, size, shape and surface 
characteristics of medications as well as a patient’s body position are crucial for the delivery of 
medications (Chisaka et al., 2006, Hansen et al., 2008). 
There have been some attempts to quantify the extent to which difficulties swallowing solid 
medications affect the population. In a study of 792 customers (69-89 yrs) of community 
pharmacies in England who pharmacists suspected may have difficulties swallowing tablets, 60% 
acknowledged having problems (Strachan and Greener, 2005). Difficulties swallowing tablets and 
capsules accounted for an average of 22% of nursing home residents in the UK, based on a survey 
of 540 nurses (Wright, 2002). In the USA, up to 40% of 64 residents in an aged care facility 
reported having difficulties swallowing tablets and capsules while 20% of a control group with an 
average age of 30 had the same problem (Kottke et al., 1990). 
Difficulty swallowing solid dose medication is ideally addressed by the prescriber finding an 
alternative dosage form, which may require the prescribed medicine to be compounded into a liquid 
preparation or a change to a different medicine (Burridge and Deidun, 2011). However, in the 
absence of an alternative, solid dosage forms are invariably modified by patients and carers into a 
form that can be swallowed. For example, in the UK, 61% of staff in nursing homes crushed or 
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opened medications for patients (Wright, 2002), and 25% of oral doses were altered in a mental 
institution (Stubbs et al., 2008). In Australia, medications were altered before being given to the 
patient in 34% of 408 observations in aged care facilities (Paradiso et al., 2002), and nurses at 79% 
of 97 health facilities altered medicines to ease administration (Nissen et al., 2009). This commonly 
involves crushing tablets or opening capsules and mixing the contents into food or fluids such as 
apple sauce, jam, custard, yoghurt, honey or juice (Nissen et al., 2009, Lee et al., 1996, Gidal et al., 
1998, McLean et al., 2001, Fay et al., 2005, Jann et al., 1986, Damle et al., 2002). Patients suffering 
from dysphagia often have their fluid and dietary intake managed by the use of thickening agents in 
order to ensure safe swallowing and avoid aspiration into the airway (Jukes et al., 2012). 
Medications for these patients may also be delivered by crushing and mixing with ‘thickened 
fluids’(Nissen et al., 2009), which are liquids such as water or juice thickened to the required 
viscosity. There are generally three thickness levels used, with the viscosity prescribed often 
increasing with severity of dysphagia (Jukes et al., 2012). 
While it is generally recognised by health professionals that tablets or capsules that are designed to 
have modified release properties should not be crushed due to the potential for toxicity, other 
medications are not often associated with any potential for negative outcome (Nguyen et al., 2014). 
Immediate release solid medications are designed to disintegrate and dissolve quickly in the 
gastrointestinal tract, so crushing may be expected to result simply in a slightly faster absorption. 
However, while this is the case for some medications (Lippert et al., 2005, Dodds, 1989) crushing 
could result in higher bioavailability (Zafar et al., 2009, Henney et al., 2008) due to enhanced 
dissolution and mass transfer, but it may also lead to sub-therapeutic drug levels due to loss of the 
dose during crushing and transfer (Paradiso et al., 2002, Manessis et al., 2008). Additionally, it is 
recognised that delivering medications with food or drink may impact drug bioavailability, with 
fruit juices such as grapefruit, orange or apple juice affecting absorption of numerous medicines 
(Bailey, 2010, Jeon et al., 2013, Lilja et al., 2005) and foods potentially affecting physiologic 
conditions such as gastric emptying (Damle et al., 2002, Fleisher et al., 2010). Generally, crushing 
tablets or opening capsules and mixing with a small quantity (e.g. two tablespoons) of food such as 
pudding, yoghurt or apple sauce does not significantly alter bioavailability (Lee et al., 1996, Gidal 
et al., 1998, McLean et al., 2001, Fay et al., 2005). However, mixing crushed phenytoin tablets with 
pudding resulted in impaired absorption in comparison to the use of apple sauce (Jann et al., 1986) 
and mixing enteric-coated beads of didanosine with yoghurt or apple sauce delayed absorption 
(Damle et al., 2002). The effect of mixing crushed tablets into thickened fluids on drug absorption 
has not previously been addressed, but there is evidence that absorption of whole digoxin, penicillin 
and metformin tablets may be reduced when consumed with guar gum as a source of dietary fibre 
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(Huupponen et al., 1984, Gin et al., 1989) and dissolution rate of benzoic acid tablets is reduced 
when tested in dissolution media thickened using xanthan gum or guar gum (Sarisuta and Parrott, 
1982). Alterations in bioavailability such as this are of particular concern for drugs that have a 
narrow therapeutic index because the concentration absorbed into the blood stream may not reach 
that required to elicit the therapeutic effect. 
In a preliminary study, the release and dissolution of crushed amlodipine, atenolol, carbamazepine 
and warfarin tablets were tested with six foods and drinks that are frequently used in the clinical 
setting as mixers for crushed medications (water, orange juice, honey, yoghurt, strawberry jam and 
water thickened with Easythick powder) in comparison to whole tablets. Atenolol dissolution was 
unaffected by mixing crushed tablets with the thin fluids, water or orange juice (Table 2-1, Figure 
2-1. Thick food products such as honey jam and yoghurt had a relatively small and drug-dependent 
impact on dissolution. In particular, it was found that jam delayed the dissolution of amlodipine in 
comparison to whole and crushed tablets, and yoghurt was associated with large variation in 
dissolution between replicate tests for amlodipine and carbamazepine. While jam, yoghurt and 
honey slowed dissolution for crushed carbamazepine and warfarin, this actually served to create a 
release profile that was more like that of the whole tablet than the crushed tablet, which reinforces 
the fact that each dosage form has the potential to respond differently to crushing and mixing with 
vehicles such as these (Manrique-Torres et al., 2014).  
The major outcome from this preliminary work was the observation that mixing medications with 
thickened water significantly delayed dissolution for all four medications studied (Figure 2-1,Table 
2-1). These provide the basis to formulate new hypotheses on the effect of thickeners commonly 
prescribed for the management of fluid ingestion in swallowing complications on drug release: 
 Thickened water at the viscosity levels specified for the management of dysphagia delays drug 
release. 
 Drug release is affected to a greater extent by high-viscosity fluids than low-viscosity fluids.  
Five thickening agents were chosen based on the list of products available in Australia so that the 
composition and the percentage recommended (levels 150, 400 and 900) were known. A model 
medication was selected from the dosage forms studied previously (Manrique-Torres et al., 2014). 
Atenolol conventional crushed tablets (50 mg/tablet) so it is a hydrophilic formulation, highly 
soluble in water o aqueous solutions so that dissolution is not controlling drug release.
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Table 2-1. The percentage dissolution (mean ± standard error; n = 3) in simulated gastric fluid at 30 
minutes for amlodipine, atenolol, carbamazepine and warfarin whole tablets delivered with 15 g 
water and crushed tablets mixed into 15 g of various vehicles. Within each column, measurements 
with the same superscript letter are not significantly different (P<0.05). Data taken from (Manrique-
Torres et al., 2014). 
 Percentage of drug dissolved at 30 minutes 
 Amlodipine Atenolol Carbamazepine Warfarin 
Whole tablets 100.7 ± 1.5 
a
 98.1 ± 1.1 
a
 57.0 ± 2.8 
ac
 44.9 ± 7.1 
a
 
Crushed tablets:     
 Water 99.5 ± 0.4 
a
 99.8 ± 0.2 
a
 76.7 ± 1.0 
a
 89.5 ± 1.3 
b
 
 Orange juice 100.2 ± 0.3 
a
 100.0 ± 0.0 
a
 78.7 ± 2.4 
a
 79.3 ± 7.4 
b
 
 Honey 94.3 ± 2.8 
ac
 99.2 ± 0.5 
a
 40.1 ± 2.9 
ac
 43.6 ± 3.2 
a
 
 Strawberry jam 67.7 ± 4.4 
bc
 100.0 ± 0.0 
a
 37.4 ± 2.4 
ac
 37.8 ± 5.1 
ad
 
 Yoghurt 82.8 ± 13.5 
acd
 100.5 ± 3.0 
a
 51.2 ± 11.4 
ac
 53.0 ± 1.3 
a
 
 Easythick (level 900) 52.4 ± 5.6 
bd
 50.1 ± 2.7 
b
 13.4 ± 4.0 
bc
 14.9 ± 1.0 
cd
 
 
Dissolution testing conditions of apparatus II were chosen in a single acidic media and this quality 
does not affect the solubility of the drug and resembles drug administration in fasted state. The in 
vitro dissolution test performed under specific conditions can be used as a prognostic tool for 
evaluating the bioavailability of certain drugs (Amidon et al., 1995). While it cannot entirely 
replace in vivo testing, in vitro dissolution testing can provide insights on the physicochemical 
process involved and provide an indication of whether in vivo tests are warranted (Dressman et al., 
1998). Viscosity of the thickening agents was assessed at a single shear rate of 50 s
-1
 to determine 
its influence on the release of the drug.   
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Figure 2-1. Dissolution of amlodipine (a,b), atenolol (c,d), carbamazepine (e,f) and warfarin (g,h) in 
simulated gastric fluid using whole tablets and crushed tablets mixed with water (a,c,e,g) and 
crushed tablets mixed with orange juice, honey, jam, yoghurt and thickened fluid (Easythick at 
thickness level 900) (b,d,f,h). The data shows mean ± standard error for 3 replicates. Data taken 
from (Manrique-Torres et al., 2014). Release and dissolution from five thickening agents (Easythick 
Advanced, Janbak F, Karicare, Nutilis, Viscaid) was investigated at three thickness levels (150, 
400, 900) using crushed atenolol tablets. Whole and crushed atenolol tablets in water were re-tested 
at the same time for comparison.  
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2.2 Methods 
Atenolol 50 mg immediate release tablets (Sandoz) was used as a model drug and for being one of 
the common medicines modified in hospitals (Nissen et al., 2009). Atenolol was also chosen for its 
high solubility in water and for the presence of a chromophore within the chemical structure to 
enable analysis using UV spectroscopy. Six commercial food thickening agents (Easythick, 
Easythick Advanced, Janbak F, Karicare, Nutilis, Viscaid) were selected as a vehicles for drug 
delivery (Table 2-2) and prepared as directed by the manufacturer at three thickness levels indicated 
for dysphagic patients (Jukes et al., 2012); mildly thick (level 150), moderately thick (level 400) 
and extremely thick (level 900). Spoon measurements of the powder were converted to weight 
(Table 2-2) and added into water to reach the desired percentage (% w/v). Mixtures were stirred 
using a stick blender for 3 minutes until the powder was dispersed. Samples were maintained at 4°C 
overnight to ensure hydration, swelling and microbiological stability, and then equilibrated at room 
temperature before testing. 
2.2.1 Vehicle characterisation 
The pH of the vehicles was measured using an S220 SevenCompact pH meter (Mettler-Toledo, Port 
Melbourne, Vic) and a pre-calibrated pycnometer was used for density measurements. Rheology of 
thickening agents were measured with an AR 1500ex (TA Instruments) rheometer using aluminium 
large vane of 21.92 mm stator inner radius, 10.98 mm rotor inner radius, 15.04 mm cylinder 
immersed height and 11000 μm gap and a cup. The reason to select this geometry was based on the 
physical attributes of the samples, for instance nutilis or karicare thickeners both formulated with 
starch formed highly structure fluids and in combination with temperature samples were difficult to 
manipulate using other geometries. The steady state flow curves and peak flow curves were 
measured for three independent thickened samples prepared at 37°C at each level studied. 
2.2.2 Effect of dissolution of the thickened fluids on the viscosity of the media 
A 15 mL sample of each thickener prepared at level 900 was loaded into each of the dissolution 
vessels containing 900 mL of SGF. The dissolution of the samples was measured (apparatus II, 
37°C, 50 rpm, 3 hours). A 20 mL sample was withdrawn from the vessels and replaced with 20 mL 
of fresh media at 15, 30 and 180 minutes. Peak flow curves at 37°C, 50 s
-1
 for 180 seconds, and 
steady state flow curves for 180 minute samples, were measured using AR-G2 (TA Instruments) 
with a cone and plate fixture, 40 mm diameter and 2° angle at 37°C for each sample in triplicate. 
For comparison, another set of thickened fluids were prepared at level 900. This time the amount 
thickener was calculated to produce the same thickness as in 900 mL of SGF, and placed into the 
roller mixer for 24 hours to guarantee complete dispersion. The viscosity of the samples was 
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measured at 37°C using an AR 1500ex with concentric cylinder at 37°C with a peak hold test at 50 
s
-1
 and mean viscosities reported. 
2.2.3 Drug release and dissolution 
Two atenolol tablets were crushed using a mortar and pestle to produce adequate drug 
concentrations for spectrophotometric detection. The powder obtained was then transferred into a 
30 mL plastic cup filled with 15 g of the vehicles, as an estimation of the quantity typically used for 
medication delivery. Powder medication was incorporated by hand with a metallic spatula and 
agitated for one minute to disperse the solid. For comparison, whole tablets delivered with 15 mL 
water were tested. USP dissolution test apparatus II (VK7000, Varian, Mulgrave, Vic) was used 
with 900 mL of pH 1.2 simulated gastric fluid (SGF) without enzymes (British Pharmacopoeia 
commision, 2012) at 37°C and a paddle rotation speed of 50 rpm (British Pharmacopoeia 
commision, 2012, United States Pharmacopoeia, 2011a). Dissolution media recommended for each 
drug varied between the USP and BP; in this study a single standard environment was chosen to 
allow direct comparison of the drug in multiple vehicles. 
Dispersions of the drug and the vehicle were placed into the dissolution vessel and 5 mL samples 
were collected at 1, 3, 5, 10, 15, 30, 60, 90, 120,150 and 180 minutes through a stainless steel 
cannula assembled with full flow filter (10 μm, Varian) into 5 mL plastic syringes. 5 mL of fresh 
SGF was replaced immediately into dissolution vessels at every sampling point. Dissolution tests 
were also performed for the vehicles without drug as the control. Samples were filtered through 
0.45 μm nylon membranes (Millipore). A calibration curve of atenolol in SGF was prepared using a 
stock solution containing two atenolol, tablets dissolved in 1 L SGF and absorbance measured at 
274 nm using a Spectrophotometer Hitachi U-1900, (Scientific Instrument & Optical Sales, 
Brisbane, Qld). To account for background absorbance associated with the vehicles, results for the 
controls were subtracted from the absorbance of the vehicle containing drug. Cumulative 
percentage of the drug being dissolved was obtained and plotted against sample time. All tests were 
repeated in triplicate. 
2.2.4 Statistical analysis 
The results were analysed for differences in drug dissolution from food vehicles and thickening 
agents with one way ANOVA (p<0.05) and a Bonferroni post hoc test using GraphPad Prism 
version 5 (GraphPad software, San Diego, CA, USA). 
  
 34 
2.3 Results 
2.3.1 Vehicle characterization 
The results of the physicochemical charaterisation are presented in Table 2-2. Differences in the 
reported viscosity values at 50 s
-1
 were measured in spite of being classified at the same thickness 
level. At level 900 the reported viscosity values were above 1250 cP. At level 400, viscosity values 
at 50 s
-1
 were about 400 cP and at level 150 varied between 15 to 260 cP for Easythick Advanced, 
Janbak F, Karicare and Viscaid. Viscosity of Nutilis was higher than the others at each level. In 
fact, Nutilis contains a variety of gums and starch that thicken upon storage, and shear history also 
affects viscosity measurements. 
Table 2-2. Physicochemical characteristics and rheological attributes of the commercial thickeners 
used in this study. Spoon measurements indicated for each product were converted to weight and 
added to water to give the concentration (% w/v) for each thickness.  
Vehicle Brand 
 
Composition
a
 Thickness Conc. 
(%w/v) 
pH Density Viscosity 
(cP)
b
 
Type of 
flow 
Easythick 
Advanced 
Flavour 
Creations 
maltodextrin, 
xanthan gum, 
vitamin C,  
calcium chloride 
Level 900 4.32 4.4 1.01 1250 Non- 
Newtonian
c
 
Level 400 1.70 4.8 1.00 414 
Level 150 0.87 4.8 1.00 176 
Janbak F Janbak 
Industries  
xanthan gum  Level 900 2.2 6.0 0.99 1252 Non- 
Newtonian
c
  
  Level 400 1.15 6.2 1.00 465 
  Level 150 0.76 6.2 1.00 260 
Karicare  Nutricia maltodextrin, 
maize starch,  
carob bean gum 
Level 900 40 5.1 1.03 1711 Non- 
Newtonian
c
 
  Level 400 20 5.3 1.03 483 
  Level 150 8 5.4 1.00 15 
Nutilis  
 
 
Nutricia maltodextrin, 
modified maize 
starch, tara gum, 
xanthan gum, 
guar gum 
Level 900 16 5.6 1.02 4090 Non-
Newtonian
c
  
Level 400 12 5.7 1.02 3380 
Level 150 8 5.7 1.02 1860 
Viscaid Janbak 
Industries 
guar gum Level 900 1.4 6.3 0.99 1681 Non-
Newtonian
c 
 Level 400 0.67 6.2 0.99 465 
Level 150 0.33 6.5 0.99 47 
a
 taken from the product label; 
b
measured at 50 s
-1
 and 37 °C; 
c
 AR 1500ex; 
d
 HAAKE MARS III 
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2.3.2 Effect of dissolution of the thickened fluids on the viscosity of the media 
Addition of thickened fluids, as a 15 g bolus, into the dissolution vessel had negligible influence on 
the viscosity of the dissolution media (Table 2-3), as shown by the level 900 thickeners tested at 15 
minutes and 3 hours. Xanthan gum based products (Easythick Advanced and Janbak F) exhibited 
the greatest values of all the fluids after 3 hours of the experiment. The viscosity profile of the 
media at the end of dissolution testing exhibited Newtonian behaviour for karicare, nutilis and 
viscaid so the plots of the shear stress against shear rate were linear (Table 2-3, Figure 2-2). On the 
contrary, the media containing traces of janbak or Easythick were non-Newtonian fluids so they 
were not linear. 
Table 2-3. Contribution of thickened fluids (added as a 15 g bolus) to the viscosity of the media 
(900 mL simulated gastric fluid) with time. Viscosity taken at single shear rate of 50 s
-1
 at 37°C for 
samples taken at several time points for three replicates.  
Dissolution media viscosity (cP)
a
 
 15 min 30 min 180 min  
Easythick Advanced 0.86 1.27 1.27 
Janbak F 0.80 0.91 1.57 
Karicare 0.80 1.30 1.31 
Nutilis 0.69 0.90 0.93 
Viscaid 0.68 0.80 0.82 
a
AR-G2 cone and plate fixture  
For comparison, the viscosity of the thickener was measured assuming complete dispersion of the 
thickener in the media (Table 2-4). All viscosity values were higher than those measured in the 
dissolution test of the 15 g bolus, suggesting that full dissolution of the thickened fluids were not 
achieved within 3 hours of dissolution testing.  
 36 
Shear rate (1/s)
100 200 300 400
S
h
ea
r 
st
re
ss
 (
P
a)
0.1
0.2
0.3
0.4
0.5
Janbak F 
Easythick adv 
Nutilis
Karicare
Viscaid 
 
Figure 2-2. Shear stress versus shear rate curves for thickened fluids at level 900 measured using 
the TA 1500 rheometer for samples taken at 180 minutes. The individual points are representatives 
of one measured value at 37°C. 
Table 2-4. Viscosity (at single shear rate of 50 s
-1
)
 
of the thickeners dispersed into 900 mL media, 
with the calculated concentration of the thickener shown. 
Complete dispersion  
Vehicle  concentration (%w/v) viscosity (cP)
b
 
Easythick Advanced 0.07 5.80±2.25 
Janbak F 0.04 5.92±0.01 
Karicare 0.67 1.66±0.67 
Nutilis 0.27 1.61±0.32 
Viscaid 0.02 1.04±0.02 
b
AR 1500ex concentric cylinder 37°C 
 
2.3.3 Dissolution experiments  
Atenolol whole tablets exhibited very rapid dissolution in SGF, with more than 85% of the drug 
dissolved in the first 10 minutes and complete dissolution achieved by 30 minutes (Figure 2-1) 
(Manrique-Torres et al., 2014). As a general guide, the amount of drug measured in a dissolution 
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test for immediate release tablets should be not less than 85% of the labeled amount within 30 
minutes according to the FDA (Food and Drug Administration, 1997).  
Thickened water at thickness level 150 caused a minor and non-significant delay in dissolution; at 
least 85% of the medication was released and dissolved within 30 minutes with all of the products, 
except Janbak F which allowed dissolution of only 76% (Table 2-5). At this level it was observed 
that when added to the dissolution vessel, thickened fluids containing the crushed tablets initially 
became dispersed and mixed with SGF but later formed a single lump, and that lump only broke 
into smaller pieces for Nutilis. 
At level 400, Easythick Advanced and Janbak F significantly slowed the dissolution of atenolol 
(Figure 2-3), allowing only 46 and 68% dissolution respectively at 30 minutes in comparison to 87 
– 98% for the other thickened fluids at the same thickness and the whole tablet or crushed tablet 
with water (Table 2-5). Observations of the samples loaded into the vessel indicated that either they 
remained as a single mass for the whole experiment (Easythick Advanced, Janbak F and Karicare) 
or broke into small pieces (Nutilis, Viscaid) and later formed a single clump (Nutilis). 
When used at level 900, all of the thickened fluids retarded dissolution when compared with whole 
tablets or crushed tablets in water, with 36 – 62% release in 30 minutes (Table 2-5) and a great deal 
of variation between replicate tests (Figure 2-3). The samples were all observed to remain in a 
single lump for the whole experiment, avoiding complete mixing with the dissolution media. Lack 
of mixing was confirmed for level 900 thickeners by testing dissolution media viscosity at 15 
minutes and 3 hours into the dissolution test, with all values being lower than measured when the 
thickener was completely dispersed in the dissolution media Table 2-5. 
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Table 2-5. The percentage dissolution (mean ± standard error; n = 3) in simulated gastric fluid at 30 
minutes for atenolol mixed in water or a thickened fluid prepared at three thickness levels. 
Measurements with the same superscript letter are not significantly different (P<0.05). 
 Percentage of drug dissolved at 30 minutes 
Whole tablets with water 97.0 ± 2.7 
a
 
Crushed tablets in water 96.0 ± 0.9 
a
 
Crushed tablets in thickener at: Level 150 Level 400 Level 900 
 Easythick Advanced 87.0 ± 2.3 
acf
 68.0 ± 5.8 
bcg
 36.2 ± 1.4 
d
 
 Janbak F 75.6 ± 8.2 
ace
 46.0 ± 5.1 
bd
 42.2 ± 6.0 
dg
 
 Karicare 96.5 ± 5.0 
a
 97.6 ± 6.4 
a
 53.3 ± 11.1 
deg
 
 Nutilis 85.9 ± 0.4 
acf
 86.6 ± 2.9 
acf
 47.1 ± 3.4 
dg
 
 Viscaid 88.1 ± 0.8 
acf
 91.0 ± 1.3 
ac
 61.5 ± 8.7 
defg
 
2.4 Discussion 
The most notable outcome from this study was that thickened fluids, prepared using commercial 
powder thickeners that are designed to produce a thickness that improves the likelihood of 
dysphagic patients to be able to safely swallow liquids, can significantly delay dissolution of drugs 
mixed into them. All five thickener tested retarded release of atenolol, which was unaffected by any 
of the food and drink products, when tested at level 900 in a previous research (Manrique-Torres et 
al., 2014). Furthermore, the thickeners based on xanthan gum also affected dissolution when used at 
the intermediate thickness, level 400. Other countries may use even thicker consistencies, for 
example in the USA the thickest level is ‘spoon thick’ which is ƞ50 >1750 cP (Jukes et al., 2012), 
which may be expected to retard drug release to an even greater extent than that observed here. 
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Figure 2-3.Dissolution profiles in simulated gastric fluid for crushed atenolol tablets mixed with the 
thickened fluids Easythick Advanced, Janbak F, Karicare, Nutilis and Viscaid at three viscosity 
levels: a) level 150, b) level 400 and c) level 900. The data shows mean ± standard error for 3 
replicates. 
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The Biopharmaceutical Classification Scheme (BCS) classifies drugs according to two major 
physicochemical properties, solubility and permeability, that contribute to bioavailability upon oral 
administration (Amidon et al., 1995). Atenolol is a drug with high solubility but low permeability, 
and so is grouped into BCS class III (Wu and Benet, 2005). While alterations to dissolution rate 
caused by the dosage form may be of relatively low importance for BCS III medications, for which 
absorption is mostly limited by permeability, the extent of the delay in drug release caused by 
thickened fluids at level 900 may have the potential to have a clinically significant effect.  
There is the potential for interactions between food components, drugs, dosage form excipients and 
gastrointestinal contents (Persson et al., 2005). Food vehicles can form a physical barrier that 
prevents mixing with gastrointestinal fluids, making drug release difficult and reducing exposure of 
the active ingredient at the site of absorption (Shono et al., 2009, Abrahamsson et al., 2004). The 
thickening agents are all comprised of natural gums and starches which hydrate and form highly 
shear thinning viscoelastic solutions, some of which were gel-like. Polymer solution rheology 
depends on the concentration, conformation in the solvent (e.g. water) and interaction between 
polymer chains (Stokes, 2012b). The conformation of xanthan gum chains is rigid rod type (Lapasin 
and Pricl, 1995). In contrast, polymer chains of galactomannans (guar gum) are flexible random coil 
type whose shape continually fluctuates (Robinson et al., 1982), while starch is highly branched 
polymer that forms swollen granules (Morris, 1990). Xanthan gum is the only polymer that carries a 
charge; while there could be the potential for direct interaction with charged drugs, the nutritional 
information for all of the thickeners indicate that they contain sodium (e.g. Easythick Advanced 1.5 
g/100g, Janbak F 1g/100g) and this would be expected to form ionic interactions with the acidic 
groups of the xanthan gum. Consequently, it is most likely that the highly ordered xanthan gum 
network simply traps drug molecules within it, and at the higher concentrations of xanthan gum 
(level 400 and level 900) this significantly impaired drug dissolution and diffusion into the 
surrounding simulated gastric fluid. At the greatest thickness (level 900), the networks formed by 
the other products were entangled enough to affect drug dissolution. The fact that thickening agents 
containing natural gums are associated with a propensity to impair drug dissolution is unsurprising, 
since they are able to impart sustained-release properties to solid dose formulations. Notably, 
xanthan gum is better able than guar gum to retard drug release being mostly used as a sustained 
release agent of formulations (Mughal et al., 2011, Varshosaz et al., 2006). 
Water thickened with polysaccharide samples did not contribute to the rheology of the dissolution 
media as the concentration of the thickener was very low and they did not disintegrate in the media. 
The viscosity values presented in Table 2-3 were within the values reported for human gastric 
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aspirates (1.7 cP to 9.3 cP at 50 s
-1
) which are only slightly higher than that of water or SGF or 
FaSSGF (1.1 cP) (Pedersen et al., 2013). The viscosity of thickeners dispersed into 900 mL of the 
media (Table 2-4) were not remotely close to that typically used in dissolution tests for the fed 
stated (500 cP) based on approximate values calculated from extrapolation data in Radwan et al. 
(2012) for 1.4% HPMC and FDA meal (Radwan et al., 2013). It is considered that the values in here 
were unlikely to affect dissolution of a conventional dosage form delivered with water.  
Thickening agents were structured fluids with shear thinning and solid-like behaviour. At low shear 
stresses, the solutions exhibit higher viscosity. Once the shear stress applied is above a critical 
value, the solutions yield, flow or fracture and viscosity drops (Stokes, 2012b). This study 
evidenced that at level 150, viscosity value at 50 s
-1
 did not affect atenolol release for almost all the 
fluids investigated. For example, the value reported for Nutilis was 1850 cP which is a great deal 
higher than that of Karicare (15 cP) at the same shear rate. For level 400, viscosities were closer to 
400 cP except for Nutilis; however, dissolution of atenolol mixed with this thickener was not 
affected. It is suggested that viscosity at a single shear rate of 50 s
-1
 was not a good indicator for 
likelihood of impeding drug dissolution and the determination of other rheological parameters such 
as viscoelasticity may be useful to provide insights on the delay mechanisms. 
In the dissolution vessel, which represents the physiological conditions within the stomach, the 
shear rates within the media are expected to distribute from 0.2 to 92 s
-1
 at 50 rpm (Kukura et al., 
2004). Clearly there are limitations to the conclusions that can be drawn when a simple dissolution 
environment is used. Further research is required to consider other issues, particularly the effect of 
swallowing on bolus structure and integrity as this would be expected to alter drug release profile. It 
is possible that forces acting during swallowing may break up the single lump of gel into multiple 
smaller lumps before it gets to the stomach. Alternatively, with impaired swallowing some of the 
thickened fluids may remain in the pharynx and be delayed in reaching the stomach. Shear rates 
within the oral cavity, pharynx and oesophagus vary as a function of both physiological and bolus 
variables. Tongue pressure and coordination, in addition to saliva lubrication characteristics will 
affect speed of movement and potential deformation of the bolus. The viscosity, density, yield stress 
and elastic properties of the bolus interact with these physiological variables. Combined, these 
factors will have most impact for individuals with dysphagia where tongue strength and control is 
often impaired and there can be severe deficits in over- or under-production of saliva (Cassolato and 
Turnbull, 2003, Senner et al., 2004). Although the shear rate of 50 s
-1
 is most often reported to 
express the shear rate associated with swallowing, there is little evidence to support this and it is 
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likely that there are a broad range of shear rates operating within the deglutitive system (Stokes et 
al., 2013, Nicosia, 2013, Cutler et al., 1983). 
2.5 Conclusions 
Coadministration of immediate release crushed tablets with thickening agents provides a functional 
approach to medicine administration as it reduces the discomfort caused by solid dosage forms for 
patients with swallowing difficulties, but with it comes the potential for unexpected drug release 
and dissolution profiles.  
 Thickened water at the viscosity levels specified for the management of dysphagia delayed drug 
release, particularly at the greatest thickness, and with products primarily based on xanthan 
gum. This delay was not due to generalized increase in dissolution media viscosity. 
 Drug release is generally affected to a greater extent by high-viscosity fluids than low-viscosity 
fluids, but viscosity at a single shear rate of 50 s-1 was not a good indicator for effect on drug 
dissolution and the determination of other rheological parameters such as viscoelasticity may be 
required. 
In vitro release and dissolution of medications when crushed and mixed with common food vehicles 
or thickening agents may be influenced by the properties (e.g. viscosity) and structure of the carrier. 
This may be critical for certain medications with a narrow therapeutic index or when immediate 
release is required for fast therapeutic action. These findings bring into question the potential 
clinical implications of the addition of these agents to medications for the purpose of dose delivery 
and indicate that further investigation of thickened fluids and their potential to influence therapeutic 
outcomes is warranted. Where the addition of a vehicle is considered clinically necessary to aid 
medication delivery, it would be important to avoid dose alteration (e.g. crushing medicines) and 
alternate dose forms or routes of administration should be found.  
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3. Chapter 3.  Delivery of medications with polysaccharide thickeners: 
effect of the state of aggregation of the drug, incorporation methods and 
rheology 
3.1 Introduction 
Oral dosage forms are designed to address the therapeutic needs of the majority of the population 
including infants, adults and the elderly. Diverse factors such as complex and fragile physiological 
conditions and psychological issues leave patients at risk of not having their medications 
(Stegemann et al., 2010). People who are not able to use oral conventional dosage forms or who 
experience problems in the oral route (i.e caused by dysphagia) require specific drug products that 
meet those requirements and produce the same therapeutic benefit to the patient. Tablets, capsules 
and liquid dosage forms should be avoided for people with swallowing impairments due to the risk 
of aspiration and penetration into the airway (Marik and Kaplan, 2003). In the absence of 
alternatives, solid medications are commonly modified. The majority (79%) of Queensland 
(Australia) health facilities modify medications such as tablets and capsules at the bedside, 
including modified release dosage forms (Nissen et al., 2009). Oral liquid dosage forms are the 
main choice for the paediatric population (EMEA, 2013) and represent an alternative to the use of 
capsules and tablets for people with swallowing issues. In spite of being an option, thin fluids leave 
patients with dysphagia at risk of aspiration as a consequence of the poor control of liquids so these 
forms have to be strategically modified to ensure safe-swallowing. The use of thickeners to 
facilitate safe swallowing of fluids is a result of the rheological properties of these agents (Cichero 
and Lam, 2014). Once dissolved, these agents increase the viscosity of liquids (e.g water). By 
increasing the viscosity, the timing of opening of the valves involved in swallowing is better 
controlled, reducing the chance of transit straight into the airway (Garcia et al., 2010).  
Previous research has demonstrated that fluid foods and medicated thickening agents have the 
potential to negatively impact the delivery of conventional crushed tablets when they are used as a 
replacement of water, based on results from in vitro dissolution tests in Chapter 2, (Manrique-
Torres et al., 2014). The effects were drug-dependent: amlodipine and atenolol were unaffected 
when delivered with thin fluids, carbamazepine and warfarin slowly released in the presence of 
honey, jam or yoghurt, atenolol mixed with thickened water at the highest viscosity restricted 
dissolution. Effects were also thickener and viscosity-dependent, with products containing xanthan 
gum and using higher thicknesses causing the greatest restriction on release (Manrique-Torres et al., 
2014). Thus changing to another active ingredient or dosage form may improve the overall drug 
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release when thickening agents are added to ease swallowing of medications, and using a different 
thickening agent may also be appropriate. 
Whilst altering the active ingredient or using a different thickening agent may improve drug release, 
there are preparation factors that could have an impact on drug release. The aim of this 
experimental section is to determine whether the state of drug aggregation (i.e. dissolved or 
dispersed) within the thickened water is an important determinant in drug release. Paracetamol 
(acetaminophen in the USA) is a good example of an active ingredient available in several 
formulations. It is the product most commonly modified for adults and children in Queensland 
hospitals (Nissen et al., 2009) and most commonly cited as being difficult to swallow (Marquis et 
al., 2013). To allow this investigation, it is available in many different dosage forms that provide 
paracetamol in solution (syrup and dissolved effervescent tablets) and in dispersed state 
(suspension). The hypothesis tested in Chapter 3 is: 
 Limitation on drug release is reduced when the drug is dissolved rather than dispersed within 
the thickened water.  
Two approaches can be applied to test this hypothesis, firstly to vary the order of adding the 
components to allow the paracetamol to dissolve in water and then mix into thickened water, as 
opposed to the standard clinical practice of dispersing crushed tablet powder into pre-thickened 
water. The second approach is to compare the effect on drug release of thickening commercial 
products that have paracetamol dissolved (effervescent tablet, elixir) or dispersed (suspension). 
Additionally, detailed rheological characterisation of the thickened products was carried out to 
consider the contribution of viscoelasticity and yield stress to restriction on drug release. 
3.2 Methods 
3.2.1 Materials  
Panadol® (GlaxoSmithKline, Australia) immediate release tablets 500 mg, round and film coated 
(marketed in Australia with statements declaring these forms do not have any ingredient that 
improves absorption), Rapid soluble effervescent tablets 500 mg, children’s 5-12 years raspberry 
flavour elixir (48 mg/mL), and children’s 5-12 years colour free orange flavour suspension (48 
mg/mL) were used. Deionized water or deionized water thickened with Easythick (Flavour 
Creations, Brisbane, Australia) was used as the drug delivery vehicle. Easythick (contents: 
maltodextrin, xanthan gum, sodium chloride) was prepared using the quantity indicated by the 
manufacturer at the thickest level (level 900) used for dysphagic patients in Australia (Jukes et al., 
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2012). Spoon measurements of the thickener were converted to weight to provide the desired 
percentage (%w/v). To produce thickened water at level 900, each 185 mL of water required 5 
teaspoons of the thickener, equivalent to 13.5 g (7.3% w/v), so for 15 mL of water 1.1 g of 
thickener was added. 
3.2.2 Experimental design  
The role in drug release of the method used to incorporate crushed tablets into the thickened water 
was investigated by varying both the order of addition of the three components crushed tablet, 
water, thickener (powder) and the technique used to add the medication (manual versus mechanical 
high speed stirrer). The variations on the order of addition were: 
 Variant 1) thickener + water, crushed tablet (i.e. the water was thickened before the crushed 
tablet was mixed in) 
 Variant 2) crushed tablet + water, thickener (i.e. the crushed paracetamol tablet was 
suspended in the water before the water was thickened) 
 Variant 3) crushed tablet + thickener, water (i.e. the crushed tablet was mixed with the 
thickener powder before the water was thickened) 
Additionally, the potential to thicken commercially available liquid dosage forms was investigated 
using a paracetamol in solution (i.e. effervescent tablet, elixir) and suspension. 
The entire experiment was replicated three times. 
3.2.3 Preparation of solid formulations by manual incorporation  
For variant 1, which represents standard clinical practice, one immediate release paracetamol tablet 
was crushed in a mortar and pestle and the contents transferred to a 30 mL disposable plastic cup. 
Thickened water was prepared by adding 3.6 g of thickener powder to 50 mL water and mixed with 
a hand stick blender (Tiffany 200W) with stainless steel shaft at stirring level 2 for one minute until 
a uniform mass was formed, then 15 g of this thickened water was added to the cup containing one 
crushed tablet and manually mixed with a metallic spatula for 3 minutes.  
For variant 2, one paracetamol tablet was crushed and transferred to weighing paper, then to a 30 
mL disposable cup. Mortar and pestle and weighing paper were rinsed with 10 mL and 5 mL (15 
mL total) of deionized water and added into the cup. 1.1 g thickener powder gradually incorporated 
and stirrer until homogeneous.  
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For variant 3, one paracetamol tablet was crushed and transferred to weighing paper, then to a 30 
mL disposable cup. 1.1 g of thickener powder was added to the cup containing the crushed tablet 
and stirred. Then the mortar and pestle and weighing paper were rinsed with 10 mL and 5 mL (15 
mL total) of deionized water and added into the cup and mixed.  
All samples were manually mixed with a stainless steel spatula for five minutes until the mixture 
was visually homogeneous. To allow full hydration, swelling, and to avoid microbial 
contamination, after the mixing of thickener and water, samples were covered with a double layer 
of Parafilm
®
 M (Sigma-Aldrich, Pty. Ltd. Sydney, Australia) and kept at 4°C overnight prior to 
dissolution testing. For variant 3, the thickened water prepared overnight was manually mixed with 
the crushed tablet 15 minutes before dissolution testing.  
Weights of the intact tablet, mortar and pestle with and without residuals, empty disposable cup and 
with crushed contents were taken.  
3.2.4 Preparation of solid formulations by mechanical incorporation 
In order to use an overhead stirrer for mechanical incorporation, the quantity prepared was up-
scaled to produce an appropriate volume. Three and half paracetamol tablets were crushed in a 
mortar and pestle and the solid transferred into a 100 mL glass beaker.  
For variant 1, thickened water was prepared by adding 3.6 g of thickener powder to 50 mL of 
deionized water in a measured cylinder and mixed.  
For variant 2, 50 mL water was added to the beaker containing crushed tablets, and then 3.6 g 
thickener powder was added and mixed.  
For variant 3, 3.6 g thickener powder was added to the beaker containing crushed tablets, and then a 
volume of 50 mL of water was added and mixed.  
All the samples were mixed using an IKA® RW20 digital overhead stirrer, with a crossed blade 
impellor (Thermo Fisher Scientific Australia Pty Ltd, Scoresby, Australia) at 400 rpm for five 
minutes. For the purpose of de-aeration, 30 g of mechanically mixed samples and thickened water 
used in variant 1 were transferred to 50 mL centrifuge tubes and centrifuged (Eppendorf Centrifuge 
5804 R, VWR International, Pty Ltd, Brisbane, Australia) at 2000 rpm for two minutes at 20°C. 
These were then covered with a double layer of Parafilm® M kept at 4°C overnight prior to 
dissolution testing to allow full hydration, swelling, and avoid microbial contamination. For variant 
1, the thickened water was recombined in a glass beaker after removal from refrigerated storage and 
mixed with the crushed tablets. 15 g of samples (equivalent to 1 crushed tablet) were weighed into a 
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30 mL disposable plastic cup 15 minutes before dissolution testing.  
Weights of the intact tablet, mortar and pestle with and without residuals, empty disposable cup and 
with crushed contents were taken. 
3.2.5 Preparation of liquid formulations  
The quantity of thickener added was the quantity required to thicken water to level 900. A dose of 
15 mL of elixir or suspension formulations were measured, placed into 30 mL disposable plastic 
cup, 1.1 g of thickener powder was added and mixed with a stainless steel spatula for 5 minutes to 
ensure the thickener was well dispersed. One effervescent tablet was dissolved in 100 mL water, 
and then 7.3 g of thickener powder was added and mixed until a thick solution free of powder was 
formed. Thickened samples were covered with a double layer of Parafilm® M and kept at 4°C 
overnight.  
3.2.6 Drug release and dissolution 
For the dissolution studies, prepared samples were removed from refrigeration and allowed to sit at 
room temperature 15 minutes prior to commencement of dissolution testing. The samples were 
tested using the USP dissolution apparatus II (VK7000, Varian, Mulgrave, Vic) with 900 mL of 
simulated gastric fluid (SGF) pH 1.2 without enzymes (British Pharmacopoeia commision, 2012) at 
37°C and paddle speed of 50 rpm. 3 mL samples were collected at 1, 3, 5, 10, 25, 30, 60, 90, 120, 
150, 180 minutes through stainless steel cannula assembled with flow filter (10 μm, Varian) into 3 
mL plastic syringes and 3 mL of fresh SGF was added at every sampling point (United States 
Pharmacopoeia, 2011b). In this study we used one dissolution environment to allow direct 
comparison of multiple dosage forms.  
Samples were filtered through 0.45 μm nylon membranes (Grace Davison Discovery Sciences, 
Alltech Associates Pty Ltd Vic) and diluted to obtain the desired concentrations to enable readings 
using UV spectroscopy. A calibration curve was constructed and the absorbance of paracetamol 
samples was measured at 244 nm Hitachi U-1900 Spectrophotometer, (Hitachi Australia Pty, Ltd, 
Sydney, Australia). Whole tablet in 15 mL water, crushed tablet in 15 mL water (dispersed by 
agitation with a metallic spatula), the elixir, suspension and dissolved effervescent medications 
without thickener were performed for comparison. Thickened water without medication was 
measured as control. To account for background absorbance associated with the thickener, 
absorbance readings for the control were subtracted from the absorbance of the samples containing 
drug. Cumulative dissolution of paracetamol was plotted against time and analysed for differences 
in dissolution with one way ANOVA (P<0.005) and a Bonferroni post hoc test using GraphPad 
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Prism version 6 (GraphPad software, San Diego, CA, USA). The cumulative release versus time 
plots were analysed using SigmaPlot 12.0 (Systat Software, Inc. San Jose, CA, USA) with the 
Korsmeyer-Peppas curve fitting model and similarity factor (𝑓2), which is most often applied to the 
kinetics of drug release. 
3.2.7 Rheological measurements 
Samples were prepared following the same conditions and at the same time as for dissolution 
testing. Rheological attributes of the elixir and dissolved effervescent tablet without thickener were 
measured in a stress controlled rheometer G2 (TA instruments C/O Waters Australia, Pty, Ltd, 
Sydney, Australia) using cone and plate titanium 40 mm, 2 deg, 63 μm truncation attachment at 
37°C. Samples were equilibrated for 2 minutes prior to measuring. The cone and plate was used to 
give constant shear rate throughout the sample so the viscosity does not vary within the geometry. 
Thickened samples were also measured in the cone and plate, but for several measurements 
artefacts arose including slip, and confinement of undissolved particulates from the comminuted 
tablets; such phenomena are described in detail by Davis and Stokes (Davies and Stokes, 2008). To 
overcome these particular issues, a vane-in-cup geometry was used, which is appropriate to 
characterise the rheology of structured fluids with characteristics of a weak gel that contains yield 
stress, as described in Stokes and Telford (Stokes and Telford, 2004). Thickened water, suspension, 
thickened liquid dosage forms and one crushed tablet manually mixed into thickened water (variant 
1) were prepared, equilibrated at 37°C for 30 minutes and the measurements taken in a AR 1500ex 
rheometer stress controlled rheometer (TA instruments C/O Waters Australia, Pty, Ltd, Sydney, 
Australia) with a large aluminium vane at 37°C. The linear viscoelasticity of the samples were 
characterised using small amplitude oscillatory testing: the viscous (loss modulus, G”) and elastic 
properties (storage modulus, G’) were obtained as a function of frequency. Small oscillatory 
measurements were carried out on the prepared samples. Stress sweep tests were first performed 
from 0.1 to 100 Pa, 1 Hz frequency value at 37°C to determine the linear viscoelastic region. The 
stress was linear with strain across a brand frequency range at 1 Pa and therefore frequency sweep 
tests were performed from 10.0 to 0.1 Hz, with 1 Pa constant stress at 37°C.  
3.3 Results  
Based on the weight of powder contained in the cups prior to mixing with thickened water and 
assuming that 100% corresponded to 500 mg of the content declared in one tablet, between 3% to 
4% of drug was lost during the crushing, weighing, and transfer into the cups with no difference 
between method variants. This loss has not been accounted for in the results, but indicates that the 
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total % dissolution that could be obtained from the crushed tablets could reach a maximum of 96 to 
97%. 
3.3.1 Dissolution experiments 
Paracetamol is classified in the Biopharmaceutical Scheme BCS as class III, but possesses some 
attributes of the BCS class I substances (Kalantzi et al., 2006). Its solubility is not pH dependent, 
having a pKa value of 9.5, so the single pH condition used in this study would not affect 
dissolution. Paracetamol whole and crushed tablets delivered with water exhibited rapid and 
complete dissolution in SGF with over 96% of the drug released and measured in the first 30 
minutes (Figure 3-1a,Table 3-1). Similarly, paracetamol was immediately released from the elixir 
and the effervescent tablet (Figure 3-2a,b, Table 3-2). In contrast, the suspension exhibited 
moderate release under the conditions of this dissolution test, with only 34% released in 30 minutes 
(Figure 3-2c, Table 3-3). 
3.3.1.1 Modified solid dosage forms 
Using crushed tablets, the effect of the state of drug aggregation (dissolved or dispersed), the order 
of adding components, and mixing method were investigated. Using the standard clinical method of 
preparation, in which crushed tablets were mixed into 15 g of pre-thickened water (variant 1), 
resulted in only 36% paracetamol being dissolved in the first 30 minutes. This formulation also 
failed to release 85% of the medication after 3 hours testing (Figure 3-1 variant 1). Thickener 
slowed dissolution for all formulations involving crushed tablets (Figure 3-1b,c), irrespective of 
whether manual or mechanical mixing was used or the order of incorporation of the components 
(Figure 3-1b,c, Table 3-1). The manual mixing method produced formulations with faster release of 
paracetamol than mechanical mixing, with differences being 9.5% 15.2% and 13.7% at 30 minutes 
for variants 1, 2 and 3 respectively (Table 3-1). 
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Figure 3-1. Dissolution of whole and crushed paracetamol tablets delivered with 15 mL water (a), 
and crushed tablets delivered in 15 g thickened water (b, c). The crushed tablet was incorporated 
into the thickened water by manual (b) and mechanic mixing (c) and the order of addition of 
components variants 1, 2 and 3 (referred to in key). The data shows mean ± se for three replicates 
for dissolution tests performed in SGF at 37°C and 50 rpm. The lines in (b) and (c) are fits to the 
Korsmeyer-Peppas model (Equation 3-1).  
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Table 3-1. The percentage dissolution (mean ± standard error, n=3) in simulated gastric fluid at 30 
minutes (𝑡30) for paracetamol immediate release whole and crushed tablets delivered with 15 mL of 
water and crushed tablets with 15 g of thickened water using two mixing methods (manual, 
mechanical) and three order of addition variants (1,2,3). Values of % dissolution with the same 
superscript letter are not significantly different (P<0.05). Similarity factor (𝑓2) calculated respect to 
the whole tablet and Kosmeyer-Peppas release parameter was also estimated; exponent 𝑛 ± se and 
𝑟2 ± se 
 
Formulation  
% Dissolved 
𝑡30 minutes   
Similarity  
factor f2  
Korsmeyer-Peppas  
𝑛 (se)                    𝑟2 (se) 
Whole tablet 96.7% (1.3) 
a
    
Crushed tablet in: 
     Water 
     Thickened water 
 
98.3% (0.21) 
a
 
 
    
 Manual  
    Variant 1*     
    Variant 2 
    Variant 3    
Mechanical 
    Variant 1 
    Variant 2 
    Variant 3 
 
36.3% (2.8) 
bd
 
40.1% (2.3) 
be
 
35.3% (1.7)
 bd
 
 
26.8% (1.8) 
cd
 
24.9% (1.1) 
cd
 
21.6% (3.2) 
c
 
 
19.1 
20.5 
18.6 
 
15.4 
14.3 
13.0 
 
0.49 (0.018) 
0.41 (0.013) 
0.43 (0.028) 
 
0.47 (0.018) 
0.42 (0.014)  
0.42 (0.009) 
 
0.99 (2.18) 
0.99 (1.80) 
0.98 (3.44) 
 
0.99 (1.60) 
0.99 (1.33) 
0.99 (0.74) 
*Standard method used in clinical practice 
The dissolution profiles for the crushed tablets in thickened fluid were compared to the intact 
dosage form by the similarity factor f2 (Shah et al., 1998). All medications delivered with thickened 
water invariably resulted in f2 factor of less than 50 which confirms that the dissolution profiles 
were dissimilar (Table 3-1) and predicts that differences are likely to occur in vivo. The Korsmeyer-
Peppas model fitted the dissolution profiles well (𝑟2 = 0.98-0.99; Table 3-2). This is an empirical 
equation that correlates the amount of the drug released (𝑀𝑡) and the exponential function of the 
release profile (Equation 3-1)  
Equation 3-1 
𝑀𝑡
𝑀∞
= 𝑘𝑡𝑛 
where 𝑀𝑡 is the amount of drug release at time (𝑡), 𝑀∞ is the total drug released over the duration 
of the experiment, 𝑘 is the kinetic constant, and 𝑛 is the release exponent (Korsmeyer et al., 1983). 
The release exponent 𝑛 was 0.41 to 0.49, indicating primarily Fickian diffusion-controlled release.  
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3.3.1.2 Modified liquid dosage forms 
The quantity of thickener required to thicken water to level 900 was added to paracetamol elixir, 
dissolved effervescent tablet and suspension, resulting in a significant change in dissolution profile 
for each. The quantity dissolved at 30 minutes was reduced for all three formulations, with 
differences caused by addition of thickener of 52.3%, 86.4% and 22% for the effervescent tablet, 
elixir and suspension respectively (Figure 3-2). The similarity factor f2 was estimated for each 
modified medication with respect to its intact dosage form, and in all cases f2 was lower than 50 
which confirmed lack of similarity. 
Table 3-2. The percentage dissolution (mean ± standard error: n=3) in simulated gastric fluid at 30 
minutes (𝑡30) for paracetamol intact and modified liquid dosage forms with 1.1 g of thickener. 
Similarity factor (𝑓2) calculated with respect to intact formulation. Korsmeyer-Peppas release 
parameter was also estimated; exponent n ± se and r2 ± se. 
Formulation 𝑡30 minutes Similarity 
factor
 
Korsmeyer-Peppas 
  f2 𝑛 (se) 𝑟
2 
(se) 
Effervescent tablet 96.0 ± 2.1%    
Elixir  101.0 ± 3.1%    
Suspension 30.0 ± 1.3%  0.55 (0.040) 0.98 (4.81) 
Effervescent tablet + thickener 50.8 ± 2.9% 11.7 0.34 (0.026) 0.97 (4.63) 
Elixir + thickener 13.6 ± 0.7% 2.8 0.40 (0.013) 0.99 (0.68) 
Suspension + thickener 12.0 ± 4.2% 25.1 0.58 (0.021) 0.99 (0.74) 
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Figure 3-2. Dissolution of paracetamol from (a) effervescent tablet, (b) elixir, (c) suspension. 15 ml 
of medications were delivered straight from the bottle (b,c) or dissolved in water (a) (open symbols) 
or mixed with the quantity of thickener required to produce thickened water at level 900 (filled 
symbols). The data shows mean ± se for three replicates for dissolution tests performed in SGF at 
37°C and 50 rpm. The curves are fits to the Korsmeyer-Peppas model except for unthickened 
formulations in (a) and (b).  
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The Korsmeyer-Peppas model was fitted to the dissolution profiles (𝑟2 = 0.98-0.99; Table 3-2) 
except the unthickened effervescent tablet and unthickened elixir because the paracetamol was 
already in solution in these formulations. The release exponent 𝑛 was close to 0.5, indicating 
primarily Fickian diffusion-controlled release, though it varied to a greater extent for the thickened 
liquid formulations (0.34 to 0.58) than the thickened crushed tablet formulations (0.41 to 0.49). The 
Higuchi model, (Equation 1-4) could also be used to fit the dissolution data, further indicating 
diffusion as the primary mechanism of release, though the fit of the Higuchi to the thickened 
effervescent tablet was not as strong (𝑘 = 6.92 m-1; 𝑟2 0.88) as for the suspension, thickened 
suspension and thickened elixir (𝑘 = 2.12 to 7.02 m-1; 𝑟2 0.97-0.99). 
3.3.2 Rheology of the thickened medications  
All samples containing thickener exhibited non-Newtonian shear-thinning behaviour; viscosity 
values depend on the shear stress applied to the sample (Figure 3-3). Unthickened paracetamol 
suspension also exhibited non-Newtonian behaviour, reflecting the structured vehicle contained in 
the suspension. The viscosity of the elixir and dissolved effervescent tablet were very low (Table 
3-3) and remained invariable with stress, typical of Newtonian behaviour.  
A shear rate of 50 s
-1
 was chosen for comparison as it is commonly used in evaluation of fluid foods 
as an indicator of the dominant shear rate operating in the oral cavity (Stokes et al., 2013). At this 
shear rate, the elixir and effervescent tablet with no thickener exhibited low viscosity of 0.015 Pas 
and 0.008 Pas (Table 3-3). The zero-shear viscosities (i.e. at very low shear rate, <1 Pa) of the 
samples containing thickener showed higher values in comparison to the primary formulations 
without thickener. In particular, the thickened suspension exhibited extremely high zero-shear 
viscosity, being about 5 times higher than any other of the thickened formulations.  
The presence of thickener also had an effect on infinite-shear viscosity values (i.e the viscosity at 
high shear stress >100 Pa), especially the thickened suspension and thickened elixir, indicating that 
the structure had not been disrupted enough to flow in a Newtonian manner. The apparent yield 
stress, which is the stress value at which viscosity decreases by several orders of magnitude so flow 
occurs (Stokes, 2012b), also highlighted the greater ‘thickness’ of the thickened suspension (39 Pa) 
in comparison to the other thickened formulations (17-26 Pa) and the unthickened suspension (2.7 
Pa) (Table 3-3).  
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Table 3-3. Rheology of paracetamol effervescent tablet, elixir and suspension with and without 
thickener added measured at 37°C. Viscosity at 50s
-1
 was interpolated from the viscosity-shear rate 
data. Zero-shear viscosity, infinite-shear viscosity, and apparent yield stress values were 
extrapolated from one of the three replicate flow curves. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The thickened formulations were semi-solid in appearance. The mechanical spectra were obtained 
for all samples and the results expressed in terms of an elastic storage modulus (G’) and viscous 
loss modulus (G”) (Figure 3-4). In all cases, samples behave as viscoelastic solids with G’ 
dominating over G” across a substantial frequency (ω) range (cycles/sec). As these fluids flow 
above an apparent yield stress, they are referred to here as weak gels. As defined by Stokes, a weak 
gel is a substantially diluted system that displays a solid-like behavior but is also able to exhibit 
steady state flow (Stokes, 2012a). Thickened effervescent tablet and crushed tablet in thickener 
were very similar in response to the thickened water alone. 
 
 
 
 
 
 
Formulation Viscosity 
50 s
-1 
(Pas) 
Zero-shear 
viscosity 
𝑛0 (Pas) 
Infinite-shear 
viscosity 
𝑛∞(Pas) 
Yield 
stress 
𝜎𝑦 (Pa) 
Effervescent tablet 0.008 (0.001)    
Elixir 0.015 (0.000)    
Suspension 0.403 (0.010) 357 0.403 2.7 
Effervescent tablet + thickener 1.540 (0.110) 17010 0.812 19 
Elixir + thickener 3.650 (0.450) 22923 2.542 26 
Suspension + thickener 4.380 (0.152) 114389 4.424 39 
Crushed tablet + thickener  0.625 (0.029) 16056 0.761 17 
Water + thickener 0.917 (0.095) 10982 0.626 14 
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Figure 3-3. Flow curves for dosage forms with (filled symbols) and without (open symbols) 
thickener at 37°C using vane tool. One representative flow curve from three replicates is shown. 
The unthickened effervescent tablet and elixir are not shown due to low viscosity (see Table 3-3) 
that did not change with shear stress. 
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Figure 3-4. Mechanical spectrum of paracetamol dosage forms thickened samples. Shown here are 
the elastic or storage modulus G’ (Pa) (filled symbols) and viscous or loss modulus, G” (Pa) (open 
symbols) as a function of frequency (ω) expressed in Hertz (cycles/sec) at 37°C, with vane tool 
attachment. a) Effervescent tablet, b) elixir, c) suspension, d) crushed tablet and e) thickened water. 
The modulus with and without thickener are shown for the suspension; elixir and dissolved 
effervescent tablet exhibit constant viscosity. One representative sample from three replicates is 
presented.  
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3.4 Discussion 
The presence of thickened fluid, irrespective of the dosage form or the method of preparation, had a 
substantial impact on in vitro drug dissolution. The extent of the effect depended upon the 
aggregation state of the drug contained in the dosage form and on the components of the dosage 
form. It is well known that increasing dissolution media viscosity retards release by increasing 
disintegration and dissolution time (Parojcic et al., 2008, Radwan et al., 2014), but, as shown in 
Chapter 2, the quantity of thickened fluid added to the dissolution vessel in the present study was 
not enough to alter dissolution media viscosity. 
Crushing tablets and mixing with food products is common practice to help people with swallowing 
disorders to take their oral medicines (Wright, 2002, Stubbs et al., 2008, Haw and Stubbs, 2010, 
Schiele et al., 2013). Method variant 1 with manual mixing was designed to be most similar to 
typical clinical practice, in which thickened fluid is prepared and then crushed tablet added into it 
and mixed with a spatula or spoon. This standard method resulted in paracetamol dissolution being 
only 36% by 30 minutes, with a dissimilar release profile (𝑓2<50) to that of the whole tablet. As a 
general guide, the amount of drug measured in a dissolution test for immediate release tablets 
should be not less than 85% of the labeled amount within 30 minutes according to the FDA (Food 
and Drug Administration, 1997), however paracetamol dissolution did not reach this level even at 3 
hours. Importantly, since only 3-4% was lost during crushing and transfer, the remaining 15% of 
paracetamol added into the dissolution chamber was still entrapped by the thickened fluid. 
No improvement in paracetamol release and dissolution were gained by altering the method of 
preparation. For instance, mixing the tablet powder with water first, to suspend and partially 
dissolve the paracetamol prior to adding the thickener powder (variant 2) did not affect paracetamol 
dissolution. The only alteration in dissolution was caused by using mechanical instead of manual 
mixing, but this caused a significant reduction in dissolution. The treatment of the samples after 
preparation using the mechanical mixer (i.e. air elimination by centrifugation, required to stop the 
thickened fluid chunks from floating) may have been associated with the increased entrapment of 
the drug.  
The use of commercial liquid dosage forms was investigated as a potential alternative to crushed 
tablets for delivery of a thickened oral medication dose. Paracetamol effervescent tablets dissolved 
in water and paracetamol elixir were low-viscosity products (ɳ50 < 0.015 Pas) in which 
paracetamol was present in solution. These reached 100% dissolution immediately on addition to 
the test vessel. However adding thickener to these formulations increased their viscosity, which 
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negatively impacted the rate and extent of drug release into the media. The viscosity of these 
thickened formulations was higher than thickened water (ɳ50 = 0.917 Pas), and the elixir (ɳ50 = 
3.65 Pas) was more strongly affected than the effervescent tablet in water (ɳ50 = 1.57 Pas), 
indicating that the excipients within the different formulations interacted with the thickener to 
influence viscosity.  
In the paracetamol suspension, the drug is expected to be dispersed and partially dissolved in the 
structured vehicle (ɳ50 = 0.403 Pas), so not surprisingly, dissolution was slower than for 
paracetamol in solution. In fact the suspension only reached 85% dissolution after 2 hours of the 
test, with a profile that was more similar to the crushed tablet in thickened fluid (𝑓2=60) than the 
whole tablet (𝑓2<50). Addition of thickener reduced release further, producing a dissolution curve 
that was very similar to that of the thickened elixir even though the viscosity of the suspension was 
much higher (ƞ50 = 4.38 Pas). Based on the components declared on the container by the 
manufacturer, viscosity in the suspension is conferred by sorbitol and maltitol. Adding the thickener 
increased the complexity of the microstructure, increasing the zero-shear and infinite-shear 
viscosity as well as apparent yield stress to the highest values of all of the thickened formulations.  
It is suggested here that the weak gel nature of the formulations and rheological variables has a 
substantial effect on drug dissolution and release into SGF. The products with the highest elastic 
modulus (G’), i.e. greater solid-like behaviour, were associated with the greatest restriction on 
paracetamol release. Similarly, formulations with higher apparent yield stress values, i.e. 
requirement for a higher shear stress to break the structure and cause it to flow, exhibited slowest 
dissolution profiles. This indicates that rheology plays an important role in restriction of drug 
dissolution.  
Rheological parameters, such as apparent yield stress, control breakup of the swallowed bolus and 
its flow behaviour along the gastrointestinal tract. With such high yield stress values for the 
thickened elixir and thickened suspension, it is likely that shear forces along the gastrointestinal 
tract are only sufficient to partially shear the samples and as a consequence the majority of the 
thickened fluid is in a solid-like state characterised by a high zero-shear viscosity that will limit 
diffusion and dissolution. This is expected to impact on drug release and therefore availability for 
absorption. Additionally, there are multiple factors not tested in this study that could alter drug 
release from the thickened fluids and cause release in vivo to be faster and/or greater than that 
obtained here; for example the fasted or fed state determines enzyme activity in the mouth and 
gastrointestinal tract and may cause preliminary breakdown of the bolus, and peristaltic mixing, 
gastric emptying and gastrointestinal transit time may also impact the bolus.  
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It is not clear from the results whether the delayed and reduced drug levels measured in the 
dissolution test media is due to restriction on dissolution within the thickener and/or diffusion out of 
the thickener. On one hand improvement in release occurred when the paracetamol was in solution 
within the thickener, as for the dissolved effervescent tablet (50% at 30 mins), in comparison to 
being dispersed in the thickener as for the crushed tablet (36% at 30 mins). This may be taken to 
indicate that release was slower if the drug powder had to dissolve prior to diffusing. On the other 
hand, the thickened elixir and thickened suspension exhibited the same dissolution profile but the 
paracetamol was presumed to be in solution in the elixir but dispersed in the suspension. However, 
these comparisons are complicated by the different dosage forms and associated excipients involved 
(crushed immediate release tablets vs effervescent tablets, and elixir vs suspension). The excipients 
in the dosage forms interacted with the thickener and confounded the interpretation of the results. 
For example guar gum viscosity is increased by polyols (Moser et al., 2013) such as those present in 
the elixir (sorbitol) and suspension (maltitol and sorbitol) and similar effects are anticipated with 
xanthan gum. Furthermore, the quantity of thickener added to each formulation was calculated for 
use in water, so reducing the quantity added to account for the composition of the dispersing media 
would be required for complex formulations such as this (Sopade et al., 2007, Sopade et al., 2008a, 
Sopade et al., 2008b). To further investigate whether the rate-limiting step in drug release from 
thickened fluids is dissolution or diffusion, pure drug powder should be used in order to remove the 
confounding effect of excipients.  
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3.5 Conclusion 
This study demonstrated that dissolution is affected by the presence of thickeners added to facilitate 
oral ingestion of medicines. Drug release from thickened medications was unaffected by the state of 
aggregation of the drug e.g dissolved in the thickened elixir and effervescent tablet and dispersed in 
the thickened suspension. Each dosage form has the potential to respond in a different manner to the 
addition of thickening agents due the presence of excipients. The typical clinical practice approach 
of preparing the thickening agent and then adding the crushed medication with manual stirring was 
not improved by altering the order of addition or mixing method. The rheology of the thickened 
products indicated that the weak gel structures of the formulations considerably impacted drug 
dissolution and release into SGF so the greatest viscoelasticity and apparent yield stress values 
exhibited the slowest and reduced dissolution. It is suggested that thickened fluid in a solid-like 
state will limit diffusion and dissolution of the drug.  
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4. Chapter 4.  The mechanism of drug delivery from thickening agents 
4.1 Introduction 
Polysaccharide-based thickened vehicles have the potential to retard the release of oral medications 
of atenolol and paracetamol as described in Chapters 2 and 3. The aim of this chapter is to capture 
the nature of drug transport through the polysaccharide phase using atenolol as a model drug, and 
enhance knowledge on the mechanism of the drug release into gastric fluids. Specifically, the work 
aimed to determine whether the thickened vehicles primarily limit drug dissolution and/or the 
transport process of diffusion into simulated gastric fluid in vitro. 
Immediate release dosage forms are required to deliver a drug within a defined timeframe to reach 
the site of action; therefore, it is imperative that incorporation of drugs into fluids (water, juices) or 
thick vehicles (thickened fluid, yoghurt, honey) does not alter the release kinetics. The primary 
intention of loading drugs into the thickened phase is to prolong the time of oral processing for safe 
swallowing of the medications in patients with dysphagia. However, the influence of these 
hydrocolloid systems as a delivery vehicle in reducing availability of the drug for absorption is not 
well understood. Therefore, the choice of an optimal delivery vehicle may be complex and 
medication-dependent factors (i.e. dosage form, therapeutic index and physicochemical properties) 
must be taken into consideration.  
The rate of movement of material by diffusion is described mathematically by Fick’s diffusion laws 
which relate the movement of molecules due to a concentration gradient. As such, drug molecules 
have to dissolve and move out of the dosage form formulation to be effective for absorption within 
the body. Diffusion constants have been estimated in the pharmaceutical sciences field to 
understand the delivery mechanisms and optimise prospective formulations (Alvarez-Mancenido et 
al., 2008, Alvarez-Lorenzo et al., 1999, Barreiro-Iglesias et al., 2001, Lucero et al., 2013, Nakauma 
et al., 2012, Shelat et al., 2011).  
Chapter 2 and 3 reported the kinetics of dissolution of drugs into gastric fluid from thickened fluid 
matrices whilst mixing within the USP dissolution apparatus II. The kinetics of drug transport to the 
gastric fluid is a combination of: response of the thickened fluid to the shear forces in the mixing 
cell (hydrodynamics); drug dissolution in the thickened fluid; and movement of the drug through 
the thickened fluid to the gastric fluid via diffusion. The experiments highlight that thickened fluids 
affect drug transport processes, but they do not identify the rate-determining step. Hydrodynamics 
in the USP dissolution apparatus controls the stretching and breakup of the thickened fluid in the 
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gastric fluid, which thus affects the diffusive pathway into the gastric fluid. Here, we aim to 
consider the kinetics of drug diffusion process through the thickened fluid matrix in the absence of 
such hydrodynamic effects and to consider the following hypotheses: 
 Drug diffusion decreases as concentration of polysaccharide increases within the thickened 
system.  
 Viscoelasticity is a determinant of drug diffusion within the polysaccharide thickened system. 
 Reducing the diffusion pathway, by breaking the thickened fluid mass into multiple smaller 
droplets, increases drug release.  
Measuring drug diffusion using a vertical diffusion cell (also known as Franz cell or transdermal 
system) composed of two compartments enables measurement of the amount of the drug transferred 
from a donor semi-solid phase to a recipient fluid phase in the absence of shearing (Higuchi, 1961). 
This approach compares the pure movement of the drug through the polysaccharide phase through a 
membrane system and into simulated gastric fluid. Vertical diffusion cells do include mixing (by 
convection) of the dissolved species in the receptor side to guarantee distribution of the dissolved 
species. 
The model drug used in this study was atenolol at a starting concentration in polysaccharide 
solutions higher than water solubility, which is in accordance with the assumptions of the  Higuchi 
model (Higuchi 1961). The polysaccharides xanthan gum (0-2.2%), guar gum (0-1.4%) and 
maltodextrin (15, 40 and 70%) were used, which covers the concentration range used to deliver 
medications to dysphagic patients (Chapter 2). The rationale behind the choice of gums relates to 
the electric charge of the molecules; xanthan gum is negatively charged while guar gum and 
maltodextrin are neutral the rheology of xanthan and guar gum solutions exhibit non-Newtonian 
flow while maltodextrin solutions are Newtonian that may dictate the mechanism of release. For 
comparison, the diffusion of atenolol crushed tablets incorporated in xanthan gum 2.2% is assessed 
to determine the influence of tablet excipients on the movement of the drug. Subsequently, the 
diffusion coefficients established in this study are used in an equation to model the role of diffusion 
pathway length, i.e. thickened fluid droplet size, on drug release, and the model validated with drug 
dissolution measurements collected for various droplet sizes.  
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4.2 Materials and methods   
4.2.1 Materials  
The materials used in this chapter were: 
 Atenolol USP fine powder, 4-[2’-hydroxy-3’-[(1-methyl ethyl)amino]propoxy], molecular 
weight: 266.34. CAS 29122-68-7, part: 55-2467-25G, batches C135585 and C156470. 
Professional compounding chemist of Australia PCCA, 9901 South Wilcrest, Houston, Texas 
7709. 
 Atenolol Sandoz®, atenolol tablets 50 mg. Scored white tablets and film coated-tablet as declare 
by the manufacturer.  
 Janbak F, xanthan gum commercial food grade, CAS 11138-66-2, batches 42263 and J190241, 
Earlee products, 24 Propietary St, Tingalpa, QLD 4173, Australia. 
 Viscaid, guar gum commercial food grade, CAS 9000-30-0, batch: 43291, Janbak Industries, 
15-19 Contaner Street, Tingalpa, QLD 4173, Australia. 
 Maltodextrin USP, C6nH(10n+2)O(5n+1), CAS 9050-36-6, batch C151324. Professional 
compounding chemist of Australia PCCA, 9901 South Wilcrest, Houston, Texas 7709, 
Expiration date: August 01, 2014. 
 Simulated gastric fluid (SGF) comprised of 0.01 N HCI (pH 1.2 ± 0.1) was degassed for 2 hours 
by sonicating (Soniclean
®
) at 30°C prior to use. 
4.2.1.1 Preparation of polysaccharide stock solution 
The range of concentrations used in this study was selected based on two criteria: (i) the 
physicochemical properties of polysaccharide in solution and (ii) the concentration level used to aid 
swallowing. There are three concentration levels that relate to polymer-polymer and polymer-
solvent interactions, including a critical concentration for entanglement (c*) (Lapasin and Pricl, 
1995). Stock solutions of xanthan gum 2.2% w/v, guar gum 1.4% w/v and maltodextrin 70% w/w, 
which correspond to the concentration of the thickener al level 900 according to the Australian 
standardize terminology for thickened fluids (Jukes et al., 2012). They were prepared by weighing 
their corresponding amounts of the polysaccharides and deionized water (i.e. xanthan gum 2.2 g and 
97.8 g of water) using an analytical balance (Ohaus analytical plus). Concentrations were converted 
to % w/v by density. The powders were dispersed into the water and continuously stirred using a 
hand stick blender, Tiffany 200W with stainless steel shaft at set stirring level 1 for 2 minutes and 
level 2 for 30 seconds until the powder had hydrated and swelled. Samples were centrifuged at 5000 
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g for 10 minutes in a centrifuge (5804R Eppendorf, VWR international, Pty, Ltd) to remove gas 
bubbles and stored overnight until use at 4°C.  
4.2.1.2 Preparation of diluted solutions of xanthan gum, guar gum and maltodextrin 
Dilutions from the stock solutions were prepared by weighing the required quantity of stock 
solution and adding into deionized water to produce 5 mL solutions of 0.005, 0.07, 0.2, 0.4, 0.8, 1.0, 
1.2 1.5% for xanthan gum, 0.025, 0.05, 0.1, 0.33 and 0.67% for guar gum and 15, 40 and 70% for 
maltodextrin. These included the concentration levels 400 (1.2% xanthan gum, 0.67% guar gum) 
and level 150 (0.8% xanthan gum and 0.33% guar gum). These solutions, within 5 mL flat-bottom 
sample tubes, were continuously stirred in a roller mixer (Stuart SRT6D) for two hours at room 
temperature to complete hydration. Diluted solutions were kept refrigerated at 4°C for two hours. 
4.2.1.3 Preparation of atenolol powder dispersed in polysaccharide solutions 
Atenolol USP fine powder (200 mg) was weighed and added into 2 g of diluted solutions of all of 
the concentrations of xanthan gum, guar gum and maltodextrin prepared above. Then the powder 
was mixed by hand with a metal spatula for 3 minutes until a paste consistency was formed.  
4.2.1.4 Preparation of atenolol tablets dispersed in polysaccharide solutions  
For the experiments using the diffusion cells, four atenolol 50 mg tablets were crushed in a quartz 
mortar and pestle. The powder was incorporated into 2 g of xanthan gum 2.2%, 1.15%, 0.8% and 
guar gum 1.4%, 0.67% and 0.33% solutions prepared above. Samples were mixed for 3 minutes 
until a paste was formed.  
For the experiments using the dissolution tester, two atenolol tablets (50 mg/tablet) were crushed 
using a mortar and pestle. The powder was transferred into a 30 mL porcelain cup previously filled 
with 15 g of water thickened with xanthan gum 2.2% stock solution and mixed by hand with a 
metallic spatula for one minute to disperse the solid. 
4.2.1.5 Preparation of atenolol saturated solution 
The concentration solubility of atenolol was measured by adding an excess of atenolol USP powder 
into 10 mL deionized water in 15 mL centrifuge tubes. Samples were manually shaken and then 
stored at 37°C, 400 rpm in a Heidolph flat-bed rotating incubator 1000, (John Morris scientific Pty 
Ltd). Samples were manually shaken every 2 hours, taken from storage and allowed to stand and 
reach room temperature to precipitate the excess of solid. 1 mL aliquots were taken at 12, 24, 36, 48 
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hours, filtered to remove solid particles through syringe Nylon
®
 filters (25 mm, 0.45 µm, Grace 
Davison Discovery Sciences, Victoria, Australia). Samples were diluted and measured at 274 nm 
with a spectrophotometer (Hitachi U-1900, Scientific Instrument & Optical Sales, Brisbane, Qld). 
The concentrations were calculated using a calibration curve prepared in Chapter 2 (𝑦 = 0.0043𝑥 
where y is the absorbance and x is the concentration in µg/mL).  
Saturated solutions of atenolol for use in experiments were prepared by placing an excess of 
atenolol powder into 50 mL deionized water in 50 mL centrifuge tubes. Based on results from the 
measurements made every 12 hours, these tubes were manually shaken and then stored at 37°C and 
400 rpm for 48 hours. This was then filtered to remove undissolved atenolol and the filtrate used in 
experiments; the concentration of atenolol in the filtrate was measured as described above. 
4.2.1.6 Preparation of atenolol saturated solution thickened with xanthan gum  
The concentration solubility of atenolol in xanthan gum 2.2% was measured by adding excess 
atenolol powder into stock 2.2% xanthan gum. Samples were manually shaken and then stored at 
37°C, 400 rpm in a Heidolph incubator 1000. Samples were manually shaken every 4 hours, taken 
from storage and allowed to stand and reach room temperature to precipitate the excess of solid. 
Samples of 50ug were taken at 24, 36 and 48 hours and 5.94 g SGF was added, shaken and filtered 
and the absorbance measured at 274 nm. The concentrations were calculated using a calibration 
curve prepared in Chapter 2 (𝑦 = 0.0043𝑥 where y is the absorbance and x is the concentration in 
µg/mL). 
To prepare samples used in experiments, xanthan gum was added to atenolol saturated solution to 
form 2.2% xanthan gum solution and dispersed with a micro-stick blender for 5 minutes. The 
sample was left on a roller mixer for one hour to dissolve xanthan gum added and then left 
overnight to allow complete hydration.  
4.2.2 Methods  
4.2.2.1 The influence of polysaccharides on drug diffusion 
To study the influence of xanthan gum on the transfer of atenolol, several experiments were run. All 
experiments were replicated three times.  
These experiments used a vertical diffusion cell system (Logan instruments, 19 C School House Rd, 
Somerset, NJ, 08873), which comprised of six compartments each with an effective diffusion area 
of 1.76 (cm
2
), 3 mL donor and 12 mL receptor capacity, temperature controlled by a dry heat 
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thermostatically controlled system (37°C) and with centrally controlled agitation of 600 rpm. Six 
Teflon® cylindrical magnetic bars 10 mm length without ring were used for agitation.  
A regenerated cellulose dialysis membrane was used that had 10000 molecular weight cut off, was 
wet in 0.05% sodium azide and was 32 mm wide, 20.4 mm diameter and 33 mL/cm (Spectra/Pore
®
, 
Spectrum laboratories, Rancho Dominguez, CA, USA). Approximately 10 cm length of the 
membrane was cut and boiled in deionized water for 30 min. The membrane was taken with 
tweezers and rinsed in running distilled water for 3 minutes to remove solids and preparing agents. 
The membrane was cut into 6 pieces to cover the receptor orifice and kept immersed in SGF for 
about 30 minutes.  
All experiments were set up with a stirring bar (600 rpm) and 12 mL of SGF added into the receptor 
chamber, then the membrane, and then the donor chamber placed on top and clamped.  
a) Membrane compatibility 
To determine whether the media or thickened water with polysaccharides (xanthan gum, guar gum 
and maltodextrin) were compatible with the cellulose membrane, four vertical diffusion cells were 
used to test the presence of extractable materials that potentially interact with the drug or 
polysaccharides. 2 mL samples of xanthan gum 2.2%, guar gum 1.4%, maltodextrin 70%, or SGF 
(control) were placed into the donor chambers. 0.5 mL of SGF from the receptor side was 
withdrawn at 1, 2, 4, 6, 12, 24, 36 and 48 hours and the volume replaced with fresh SGF at 37°C. 
The collected samples were scanned in the spectrophotometer in the UV region 200-400 nm for 
peaks that can interfere with the detection of atenolol at λ=274 nm.  
b) Atenolol diffusion in the absence of polysaccharide solution  
The aim of this experiment was to measure the movement of atenolol across the membrane within 
the diffusion cell environment. For this experiment only, the three replicates were measured at the 
same time within three separate diffusion cells and alongside a control of SGF. On the donor side, 2 
mL samples of atenolol saturated solutions (average concentration of 20 mg/mL) or SGF (control) 
were placed on the top of the membrane. Samples of 0.3 mL from the receptor chamber were taken 
at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 300, 720 min. From these samples 250 µL was 
diluted to 2.5 mL with SGF and scanned in the range 200-400 nm. The amount of the drug 
transferred to the receptor chamber was calculated from the calibration curve of atenolol from 
Chapter 2 (𝑦 = 0.0043𝑥 where y is the absorbance and x is the concentration in µg/mL). The 
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quantity of atenolol removed from the receptor chamber in each sample was included within the 
calculation of change in concentration over time. 
The concentration of atenolol in the donor chamber was estimated using the mass balance formula:  
Equation 4-1 𝐶𝑑𝑜𝑛𝑜𝑟  =
𝐶𝑖𝑛𝑖 𝑑𝑜𝑛𝑜𝑟 ∗  𝑣𝑑𝑜𝑛𝑜𝑟−𝐶𝑟𝑒𝑐 ∗ 𝑣𝑟𝑒𝑐
𝑣𝑑𝑜𝑛𝑜𝑟 
 
where 𝐶𝑑𝑜𝑛𝑜𝑟 is the measured concentration in the donor side in mg/mL, 𝐶𝑖𝑛𝑖 𝑑𝑜𝑛𝑜𝑟  is the initial 
concentration in the donor side (mg/mL), 𝑣𝑑𝑜𝑛𝑜𝑟 is the volume of liquid in the donor side in mL, 
𝐶𝑟𝑒𝑐 is the concentration measured in the receptor side (mg/mL), and 𝑣𝑟𝑒𝑐 is the volume in the 
receptor side in mL. 
c) Drug diffusion out of polysaccharide solutions 
The diffusion of atenolol through a range of xanthan gum, guar gum and maltodextrin solutions was 
studied.  
 Atenolol (200 mg) in water thickened with xanthan gum (2 g) at 0, 0.005, 0.07, 0.2, 0.4, 0.8, 
1.0, 1.15, 1.5 and 2.2% 
 Atenolol (200 mg) in water thickened with guar gum (2 g) at 0, 0.025, 0.05, 0.1,0.33, 0.67 and 
1.4% 
 Atenolol saturated solution (c. 20 mg/mL) thickened with xanthan gum (2 g) at 2.2% 
 Crushed atenolol tablets (4 x 50 mg) mixed with xanthan gum (2 g) at 2.2%, 1.15%, 0.8% or 
guar gum (2 g) at 1.4%, 0.67% and 0.33% 
On the donor side, the 2 g sample was loaded on top of the membrane. 0.3 mL of the fluid from the 
receptor chamber was withdrawn, replaced with fresh SGF at 37°C at 5, 20, 30, 45, 60, 90, 120, 
150, 180, 210, 240, 300 and 360 minutes. From these solutions 250 µL aliquots of the samples were 
diluted up to 2.5 mL, with the exception 0.025 and 0.05% concentrations of guar gum for which 5 
mL of the solvent was used for dilutions. The amount of the drug transferred to the receptor 
chamber was calculated from the calibration curve of atenolol from Chapter 2 (𝑦 = 0.0043𝑥 where 
y is the absorbance and x is the concentration in µg/mL). The quantity of atenolol removed from the 
receptor chamber in each sample was included within the calculation of change in concentration 
over time. 
The diffusion coefficients were calculated using an equation used to describe the rate of release of 
solid drugs suspended in ointment bases into perfect sink (Higuchi, 1961):  
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Equation 4-2 𝑀𝑡 = 𝐴√𝐷𝐶𝑠 (2𝐶𝑖𝑛𝑖 − 𝐶𝑠𝑡) 
Equation 4-3 𝑘 = 𝐴√2𝐶𝑖𝑛𝑖𝐷𝐶𝑠 
Equation 4-4 𝑀𝑡 = 𝑘√𝑡 
where 𝑀𝑡 is the total amount of the drug transferred (mg), 𝐴 is the diffusion area (cm
2
), 𝐶𝑠 is the 
concentration solubility (mg/mL), 𝐶𝑖𝑛𝑖 is the initial concentration (mg/mL), 𝑡 is the time (s) and 𝐷 is 
the diffusion coefficient (cm
2
/s). 
The linearity of the Higuchi plots (total mass released in mg against square root of time) was tested 
through linear regression with a post test for equality of the slopes, and the goodness of fit was 
performed at 95% confidence using GraphPad Prism 6.0 for Windows (GraphPad Software, San 
Diego, CA). ANOVA were performed for all diffusion coefficients obtained at all polysaccharide 
concentrations (p < 0.05). Tukey’s post-hoc testing was performed to compare the diffusion 
constant obtained from each xanthan gum or guar gum concentration.  
4.2.3 Rheological parameters of polysaccharide solutions 
The viscosity profile of the xanthan gum and guar gum without drug were assessed using a G2 
rheometer with a cone and plate 40 mm diameter, 2° angle at 37°C and 40 mm titanium parallel 
plate fixtures. Before testing, samples of thickened water were removed from 4°C storage and 
allowed to equilibrate at room temperature. All samples were pre-equilibrated for 2 minutes at 37°C 
within the rheometer and steady state shear flow testing was performed from 0.1 to 10 Pa or from 1 
Pa to 100 Pa.  
Small oscillatory testing was used to measure the viscous (G”) and elastic (G’) modulus of the 
polysaccharide network, applied to new samples pre-equilibrated at 37°C. Stress sweep testing was 
used first to determine the linear viscoelastic region in the range 0.1 to 100 Hz, or 1 to 10 Hz for 
very dilute solutions. The frequency sweep test was performed at 1 Pa which was a stress value 
within the linear viscoelastic region. Very dilute samples that did not exhibit viscoelasticity were 
excluded from small oscillatory testing.  
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4.2.4 Effect of polysaccharide droplet size on drug diffusion in a shear field  
It was postulated that reducing the diffusion pathway for the dissolved model drug would enhance 
drug release from the thickened phase. The first part of this experiment evaluates if reducing the 
size of the thickened water droplet affects drug release into SGF within the dissolution tester 
environment, which incorporates stirring. The second part involved taking a theoretical approach, 
using a model to predict the fraction of drug release resulting from specific droplet sizes. 
Comparisons of the results from the experimental and theoretical approach were made using the 
similarity factor 𝑓2 (described in Chapter 3 and Apendix A 6.1.1). 
4.2.4.1 Experimental approach  
From the mixture of two atenolol tablets dispersed in 15 g of xanthan gum 2.2%, spheres of various 
volumes were prepared according to the Table 4-1. After preparation, samples were kept at room 
conditions for not more than 15 minutes. Controls of the thickened water without drug were also 
performed under the same experimental conditions. All tests were repeated in triplicate. 
Table 4-1. Xanthan gum 2.2% solutions and atenolol crushed tablets manipulated to create different 
sizes for dissolution testing. 
USP dissolution test apparatus II (VK7000, Varian, Mulgrave, Vic) was used with 900 mL of pH 
1.2 simulated gastric fluid (SGF) without enzymes at 37°C and a paddle rotation speed of 50 rpm. 
The formed spheres were loaded into the dissolution vessel and 5 mL samples were collected at 1, 
3, 5, 10, 15, 20, 30, 45, 90, 150 and 180 minutes through a stainless steel cannula assembled with 
full flow filter (10μm, Varian) into 5 mL plastic syringes. 5 mL of fresh SGF was replaced 
immediately into dissolution vessels at every sampling point. Dissolution tests were also performed 
for the controls of the food vehicles and thickening agents without drugs. Samples were filtered 
through 0.45 μm nylon membranes (Millipore). The concentrations were calculated using a 
calibration curve prepared in Chapter 2 (𝑦 = 0.0043𝑥 where y is the absorbance and x is the 
concentration in µg/mL). To account for background absorbance associated with the mixers, results 
for the controls were subtracted from the absorbance of the vehicle containing drug. The quantity of 
Sphere volume 
(mL) 
Number of 
spheres 
Calculated radius 
(cm) 
Procedure  
15 1 1.53 Spheres formed in 1 spoon of 15 cm
3
 
5.0 3 1.00 Spheres formed in 3 spoons of 5 cm
3
 
2.5 6 0.84 Spheres formed in 6 spoons of 2.5 cm
3
 
0.5 30 0.50 Spheres formed at the tip of syringes 
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atenolol removed from the receptor chamber in each sample was included within the calculation of 
change in concentration over time. 
4.2.4.2 Theoretical approach  
The Baker-Lonsdale equation, a derivation of the Higuchi equation (Siepmann and Siepmann, 
2012), describes drug release from spherical monolithic dispersions where initial drug concentration 
is greater than drug solubility in the dispersed media 𝐶𝑖𝑛𝑖>𝐶𝑆,  
Equation 4-5 
𝑀𝑡
𝑀𝑖𝑛𝑓
−
3
2
[1 − (1 −
𝑀𝑡
𝑀𝑖𝑛𝑓
)
2
3
 ] −
3𝐷
𝑅2
 
𝐶𝑠
𝐶𝑖𝑛𝑖
𝑡 
where 
𝑀𝑡
𝑀𝑖𝑛𝑓
 represents the fraction of drug released at time 𝑡, 𝐷 is the diffusion coefficient measured 
for crushed tablets in xanthan gum 2.2% in 4.2.2.1, 𝑅 is the radius of the sphere, 𝐶𝑠 is the 
concentration solubility of atenolol in xanthan gum 2.2%, was measured as described in 4.2.1.6, and 
𝐶𝑖𝑛𝑖 is the initial atenolol concentration for the dissolution experiments in 4.2.4.1 (2 x 50 mg tablets 
in 15 g thickened water; 6.67 mg/mL).  
1) Two approaches were taken, using MATLAB® R20013b software (Natick, MA, USA):The 
fraction of drug release, 
𝑀𝑡
𝑀𝑖𝑛𝑓
, at each of the times, t, that samples were taken in the 
dissolution experiments in 4.2.4.1 were predicted using the radius, R, of the spheres used in 
the dissolution experiments (Table 4-1). 
2) The droplet sizes, R, that are predicted to produce the drug release measured in the 
dissolution experiments in 4.2.4.1 were predicted using the fraction of drug release, 
𝑀𝑡
𝑀𝑖𝑛𝑓
 
calculated from the dissolution results. 
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4.3 Results  
4.3.1 The influence of polysaccharides on drug diffusion 
a) Membrane compatibility  
The media and thickened water, after exposure to the membrane, did not exhibit absorbance peaks 
in the range 200-400 nm and the membrane remained intact and not visibly altered from the 
experimental conditions. These results were the basis for the choice of this experimental approach 
for diffusion coefficient determination.  
b) Atenolol diffusion in the absence of polysaccharide solution 
Atenolol concentration in the receptor chamber SGF increased to 3.5 ± 0.17 mM (mean ± se) during 
the first 6 hours (360 minutes), with the donor chamber atenolol saturated solution, decreasing from 
the initial 20.1 ± 0.48 mg/mL (75 ± 1.79 mM) to a calculated concentration of 54.0 ± 0.81 mM. The 
concentration slowly increased to 7.4 ± 0.64 mM after 30 hours of transfer (1800 minutes) and a 
calculated concentration in the receptor cell of 27.3 ± 4.60 mM (Figure 4-1) indicating that 
equilibrium was not reached. 
c) Drug diffusion out of polysaccharide solutions 
Receptor concentration of atenolol increased slowly with time as the drug diffused across the 
membrane from the donor side containing the drug dispersed or dissolved polysaccharide solutions 
of xanthan gum, guar gum and maltodextrin. The amount of drug transferred into the receptor 
chamber was plotted as a function of the square root of time, producing straight lines as shown in 
(Figure 4-2). Linearity and equality of slopes between the three replicates for each gum and 
concentration level, as well as coefficient of determination (𝑟2), were assessed to evaluate the 
goodness of fit. Slopes that were not significantly different at 𝑝<0.05 for each concentration were 
used in Equation 4-4 to calculate the diffusion coefficient (𝐷) (Table 4-2). 
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Figure 4-1. Concentration profile (mean ± se of 3 replicates) for the transfer through a membrane of 
atenolol from a saturated solution in the donor side into SGF within the receptor cell. 
Concentrations in the receptor were measured and concentrations in the donor side were calculated 
(Equation 4-1)  
 74 
5 0 1 0 0 1 5 0 2 0 0
-1 0
0
1 0
2 0
3 0
4 0
S Q R T  (S e c )T
o
ta
l 
a
te
n
o
lo
l 
re
le
a
s
e
d
 (
m
g
)
R e p  1
R e p  2
R e p  3
 
Figure 4-2. Plot of the total amount of atenolol released from xanthan gum 2.2% versus square root 
of time as an example of triplicate data collected and regression lines fitted.  
For xanthan gum, the highest diffusion coefficient was for the very dilute solution containing 
0.005% xanthan gum, which gave a value higher than diffusion from water (Table 4-2). The 
decrease in diffusion coefficient appeared to separate into two phases (Table 4-2, Figure 4-3a) the 
first being a fast decrease as xanthan gum concentration increased from 0.07% to 0.8%. Above 
0.8% xanthan gum, diffusion was slow and the change in diffusion coefficient was small and not 
significant (0.32 x 10
-9
 ± 0.03) (Table 4-2). The diffusion coefficient of atenolol out of guar gum 
solutions followed a similar pattern (Figure 4-3b), with fast diffusion from dilute solutions and 
slower diffusion with relatively little change in diffusion coefficient above 0.33% guar gum. The 
diffusion of atenolol from maltodextrin solutions was measured for three concentrations; the 
diffusion coefficient of the lowest concentration, 15%, was the highest (0.84 x 10
-9 
m
2
/s) while the 
40% and 70% concentrations had similar diffusion coefficient values (0.24 x 10
-9
 and 0.29 x 10
-9
 
m
2
/s respectively). 
The solubility of atenolol in water has been reported as 26.5 mg/mL (Vogelpoel, Welink et al. 
2004) and was measured as 25.5 ± 1.1 mg/mL under the conditions in 4.2.1.5. Under the same 
conditions, solubility in 2.2% xanthan gum was measured as 30.3 ± 2.0 mg/mL which indicates that 
solubility was enhanced by the presence of xanthan gum. In contrast, diffusion was slower in the 
presence of xanthan gum. The diffusion coefficient for the saturated solution with 2.2% xanthan 
gum was one order of magnitude lower (1.5 x 10-10 m
2
/s) than without thickener (1.3 x 10-9 m
2
/s). 
This suggests that dissolution was not the controlling step for the movement the model drug out of 
the thickened phase, and that it was diffusion that was restricted.  
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Table 4-2. Diffusion coefficients for atenolol (mean ± standard error for 3 replicates) from xanthan 
gum or guar gum solutions estimated using the Higuchi model, i.e. the amount of atenolol released 
versus square root of time measured for 6 hours duration. One-way factorial ANOVA with post hoc 
Tukey multiple comparison test was used to compare means (p < 0.05). Within a column, means 
with the same letter were not significantly different. 
Xanthan gum Guar gum 
Concentration 
(% w/v) 
Diffusion coefficient  
(x10
-9
 m
2
/s) 
Concentration 
(% w/v) 
Diffusion coefficient 
(x10
-9 
m
2
/s) 
0 1.6 ± 0.083
a
  0 1.6 ± 0.083
a 
0.005 2.1 ± 0.081
b 0.025 1.8 ± 0.35
a 
0.07 0.69 ± 0.056
c 0.05 2.1 ± 0.058
a 
0.2 0.59 ± 0.037
cd 0.1 1.6 ± 0.13
ab 
0.4 0.86 ± 0.023
cd 0.33 0.68 ± 0.075
bc 
0.8 0.39 ± 0.044
de 0.67 0.62 ± 0.046
c 
1.0 0.27 ± 0.014
de 1.4 0.29 ± 0.0017
c 
1.15 0.38 ± 0.011
de   
1.5 0.28 ± 0.015
e   
2.2 0.26 ± 0.013
e
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Figure 4-3. Atenolol diffusion coefficient as xanthan gum (a) and guar gum (b) concentration 
increases, measured at 37°C.  
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4.3.2 Rheological parameters of polysaccharide solutions   
Maltodextrin solutions with concentration 15%, 40%, and 70% exhibited Newtonian behaviour, i.e. 
the viscosity did not change as shear rate increased; viscosity was 0.0017, 0.23 and 0.13 Pas 
respectively. Xanthan gum and guar gum solutions were both non-Newtonian at the concentrations 
measured (Table 4-3), with apparent viscosity increasing with concentration. Zero-shear viscosity, 
which is the viscosity at very low shear rates, was substantially greater for xanthan gum solutions 
than guar gum solutions whether compared as absolute concentrations (e.g. 1.5% xanthan gum vs 
1.4% guar gum) or as concentrations that produce the same dysphagia product thickness (e.g. level 
400 is produced by 1.15% xanthan gum vs 0.67% guar gum, (Table 2-2). Samples behaved as 
viscoelastic solids with G’ dominating over G” for concentrations above 0.4% xanthan gum and at 
the highest concentration measured for guar gum (1.4%).  
Although the solid-like behavior of the polysaccharide solutions slowed down the mobility of 
atenolol, the viscoelastic modulus and the zero-shear viscosity are not accurate predictors for 
diffusion. For example, the diffusion coefficient was not significantly different for concentrations 
between 0.8 and 2.2% xanthan gum but G’ and G” increased across this range (Figure 4-4). 
Furthermore, the diffusion coefficient for guar gum 1.4% was similar to 0.8-2.2% xanthan gum 
(Table 4-2), while zero-shear viscosity was very different (Table 4-3).  
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Table 4-3. Rheological parameters for xanthan gum and guar gum solutions: zero-shear viscosity 
(viscosity at low shear rates), G’ elastic or storage modulus (Pa) and G” viscous or loss modulus 
(Pa) measured at frequency of 1 Hz at 37°C and constant stress of 1 Pa. Measurements were made 
on three replicates, one representative value is shown. 
Xanthan gum Guar gum 
Concentration 
(% w/v) 
Zero-
shear 
viscosity 
(Pa s) 
G’ 
(Pa) 
G” 
(Pa) 
Concentration 
(% w/v) 
Zero-
shear 
viscosity 
(Pa s) 
G’ 
(Pa) 
G” 
(Pa) 
0 0.0009   0 0.0009   
0.005 0.0020 0.0210 0.0260 0.025 0.0011 nd nd 
0.07 0.0055 0.0650 0.1130 0.05 0.0022 nd nd 
0.2 1.326 0.3985 0.4283 0.1 0.0028 nd nd 
0.4 63 3.514 1.945 0.33 0.0413 0.2569 0.3427 
0.8 770 15.60 6.415 0.67 0.67 1.364 1.574 
1.0 3091 25.07 7.570 1.4 47.3 26.84 19.28 
1.15 4141 31.70 7.922     
1.5 9547 45.31 11.78     
2.2 15932 91.05 21.82     
nd, not determined due to non-viscoelasticity 
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Figure 4-4. Diffusion coefficient of atenolol plotted against the viscous (G”) and storage (G’) 
modulus of xanthan gum solutions, all measured at 37°C. 
4.3.3 Effect of polysaccharide droplet size on drug release 
The release of atenolol from droplets of xanthan gum 2.2% solution into SGF in a dissolution tester 
with impellor rotating at 50 rpm is shown in Figure 4-5. As droplet size reduced from 1.53 to 0.5 
cm radius, atenolol release improved.  
In order to apply Equation 4-5 certain values were measured experimentally. The concentration 
solubility, 𝐶𝑠, was measured in 2.2% xanthan gum as 30.3 ± 2.0 mg/mL. The diffusion coefficient, 
D, was measured using atenolol tablets (4 x 50 mg) crushed and mixed into 15 g xanthan gum 
solution 2.2%, and found to be 6.5 x10
-11
 ± 3.0 x 10
-12
 m
2
/s. The initial atenolol concentration, 𝐶𝑖𝑛𝑖, 
was calculated from the atenolol tablets (2 x 50 mg) crushed and mixed into 15 g of xanthan gum 
solution 2.2% for the dissolution test was i.e. 6.67 mg/mL.  
For the first step, the values for the radius R were taken as the experimental droplet sizes of 1.53, 
1.0, 0.84 and 0.5 cm (Table 4-1) which were used in Equation 4-5 to predict the fraction of release 
(𝑀𝑡/𝑀𝑖𝑛𝑓) at each of the experimental sample times (Figure 4-5). Experimental release was faster 
and higher in comparison to that predicted using the equation, and only spheres of radius 0.5 cm 
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reached a similar maximum in drug release within the experimental time scale. None of the 
predicted curves were very similar to those measured experimentally, as the similarity factor was 
low (< 50) for each, but similarity improved as droplet size reduced (Table 4-4). 
For the second step, Equation 4-5 was used to predict the radius of the sphere giving rise to the 
experimental dissolution results. The predicted droplet radius was smaller than the actual size used 
in the dissolution tests (Table 4-4); this was particularly obvious with the large droplet (1.53 cm 
radius) for which the prediction was half that of the actual value. 
Table 4-4. The variables relating to the model of drug release from spheres (Siepmann and 
Siepmann, 2012) for various sizes and for an optimal sphere size derived from the fitting 
parameters.  
Variable Sphere 15 cm
3 
Sphere 5 cm
3 
Sphere 2.5 cm
3 
Sphere 0.52 cm
3
 
𝑉𝑜𝑙𝑢𝑚𝑒 (𝑐𝑚3) 15 5 2.5 0.52 
𝑅𝑎𝑑𝑖𝑢𝑠𝑚𝑒𝑎𝑠 (𝑐𝑚) 1.53 1.0 0.84 0.50 
𝑅𝑎𝑑𝑖𝑢𝑠𝑓𝑖𝑡(𝑐𝑚) 0.76 0.63 0.53 0.40 
f2 30 40 38 43 
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Figure 4-5. A plot of the values of the 𝑀𝑡/𝑀𝑖𝑛𝑓 for sphere size of 1.53 cm to 0.5 cm experimental 
(filled symbols) and the value determined by Equation 4-5 (open symbols). The curves are fitted 
using a power law equation f = ax
b
. 
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4.4 Discussion 
The diffusion of atenolol from water thickened with xanthan gum, guar gum or maltodextrin into 
simulated gastric fluid was slowed down by the presence of the polysaccharides. Irrespective of the 
type, molecular weight, chain length and their properties in solution, biopolymers have the ability to 
affect the passage of the drug into the fluid media in comparison to the transfer in the absence of 
polysaccharide. These results were in agreement with studies that demonstrated no dependence with 
polymer chain length (Berezhkovskii et al., 1999) but influence of the size of the diffusing probes 
(Alvarez-Manceñido et al., 2006). This study determined that it was diffusion through the 
polysaccharide polymer, not dissolution of atenolol particles that was limiting drug release based on 
the fact that solubility of atenolol was higher in 2.2% xanthan gum (30.3 ± 2.0 mg/mL) than in 
water (25.5 ± 1.1 mg/mL), while the diffusion coefficient was one order of magnitude lower in 
2.2% xanthan gum (1.5 x 10
-10
 m
2
/s) than without thickener (1.3 x 10
-9
 m
2
/s). 
Diffusion was concentration-dependent. Based on the rheological testing, the c* values for 
biopolymers used in this research were close to the reported values from literature (Rodd et al., 
2000, Morris et al., 1981). At 0.025%, which is c* for guar gum (Baines and Morris, 1987), the 
diffusion coefficient was no different to water. At 0.005%, which is c* for xanthan gum (Rodd et 
al., 2000, Morris et al., 1981), atenolol diffused across the membrane more rapidly than from water. 
This suggests that the presence of xanthan gum caused atenolol to concentrate close to the 
membrane surface, resulting in faster movement of the drug along the concentration gradient.  
The semi-dilute range in this study is taken as being from 0.025% to 0.1% guar gum and 0.005% to 
0.4% xanthan gum based on rheological measurements. Mechanical spectra could not be measured 
for guar gum, and for xanthan gum the modulus values (G’ and G”) were low and similar to each 
other. At these low polysaccharide concentrations, entanglements conferred no resistance to transfer 
in the case of guar gum, but significant reduction in the rate of diffusion was measured for xanthan 
gum. This may indicate that electrostatic interaction occurred between atenolol and xanthan gum. 
Atenolol is a weak base with pKa 9.3 (Vogelpoel et al., 2004), so it would be ionized with a 
positive charge and therefore have the potential to develop an electrostatic interaction with 
negatively charged molecules. Guar gum is neutral, being composed of galactose and mannose 
(Robinson et al., 1982), while xanthan gum is negatively charged due to glucuronic and pyruvic 
acid residues amongst the uncharged glucose and mannose along its chain length (Jansson et al., 
1975). With an estimated pKa 4.5(Bueno and Petri, 2014), xanthan gum is expected to be ionized at 
the pH of water used to prepare the thickened fluid (pH water 5.2 at 23°C). Xanthan gum used in 
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this study also contained 1g/100 g of sodium, which is added to help xanthan gum to form a highly 
ordered and stable network (Morris et al., 1977), and this electrolyte maybe expected to compete 
with the atenolol for the interactions. Ionic and hydrophobic interactions (Sjoberg et al., 1999) or 
ionic interactions of gums with surfactants (Alvarez-Lorenzo et al., 1999) have been suggested to be 
responsible for decreasing diffusion.  
In the concentrated range, above 0.33% for guar gum and 0.8% for xanthan gum, transfer was not 
significantly affected by further increases in concentration, also seen above 0.5% guar gum for 
riboflavin diffusion (Tharakan, 2009). This is also associated with a reduction in flavour perception 
associated with impeded movement of flavour molecules within guar gum solutions (Baines and 
Morris, 1987). Thus, even though xanthan gum is described as being a rigid rod conformation and 
guar gum is a flexible coil (Ross-Murphy et al., 1983, Robinson et al., 1982), their effect on 
atenolol diffusion was similar. As the polysaccharide concentration increased more entanglements 
formed, visualized by the mechanical spectra which show G’ dominates over G” indicating solid-
like nature in the concentrated range. However, although both modulus values (particularly G’) and 
zero-shear viscosity increase as polysaccharide concentration increased, the lack of concomitant 
decrease in diffusion coefficient indicates that these rheological parameters are not useful indicators 
for restriction of drug movement. Similarly, rheology was not predictive for diffusivity of a 
fluorescent probe in mixtures of glucomannan and xanthan gum (Alvarez-Manceñido et al., 2006) 
and theophylline in scleroglucan gum solutions (Francois et al., 2005). Diffusion is reduced by 
increase in viscosity according to the Stokes-Einstein postulate (De Smedt et al., 1997) but only for 
diffusion of a perfect sphere through a fluid having the same bulk viscosity as the solvent (Cussler, 
1997); measurement of microviscosity (or viscosity at the microscale) has been suggested to be a 
better indicator of resistance to diffusion by the media surrounding the drug molecule (Alvarez-
Lorenzo et al., 1999). 
In addition to the rate of diffusion discussed above, the length of the diffusion pathway (i.e. droplet 
size) is also a key determinant in drug release. In Chapter 2 it was apparent that within the 
concentrated range, thickened fluid did not disintegrate and distribute throughout the SGF but 
instead remained as large droplets  (Manrique-Torres et al., 2014). This was due to the stirring 
apparatus, turning at 50 rpm, not providing enough stress to cause full disintegration. Indeed, high 
shear rates would be required to break up non-Newtonian fluids that exhibit shear thinning and 
viscoelasticity, such as xanthan gum or guar gum solutions in the concentrated range, in comparison 
to that required to break up droplets of a Newtonian fluid such as maltodextrin (De Bruijn, 1989). 
Where droplet break-up occurs it may be expected that drug release will improve, as confirmed in 
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this study by the reduction of the single mass into multiple small droplets, which resulted in faster 
and greater drug release.  
This study also showed that droplets of thickened xanthan gum do not behave as monolithic spheres 
that retain a certain diameter throughout the dissolution test, because predictions made using the 
Baker-Lonsdale equation were dissimilar to experimental values whether the equation was used to 
predict drug release profile or droplet size. The model predictions indicate that the droplet sizes 
were smaller than defined experimentally, suggesting that the droplets may have reduced in size 
during the dissolution test. It is also possible that the droplets did not remain spherical and became 
elongated as a result of the shear stress exerted by the stirring. 
A further complication in drug release from crushed tablets mixed into thickened fluids is the effect 
of tablet excipients. Transfer of atenolol from crushed tablets in 2.2% xanthan gum into SGF was 
associated with a lower diffusion constant (6.5 x 10
-11
 ± 3.0 x 10
-12
 m
2
/s) in comparison to pure 
atenolol powder (2.6 x 10
-10
 ± 1.3 x 10
-11
 m
2
/s). Therefore the presence of excipients in the dosage 
form appears to interact with the xanthan gum to further impede drug release. Fillers and binders 
used in tablets may be insoluble within the thickened fluid solution and provide a steric impediment 
to drug movement.  
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4.5 Conclusion 
The negative effect of water thickened with polysaccharides on drug transfer into SGF was 
investigated. Diffusion of atenolol, not dissolution, controlled the rate of its release from solutions 
of xanthan gum and guar gum. Rate of diffusion was dependent on the concentration of the gums in 
solution. At semi-dilute concentrations, in which some polysaccharide chain entanglement occurs, 
diffusion coefficient gradually reduced with increase in concentration. There was evidence in semi-
dilute concentrations of xanthan gum for the movement of positively-charged atenolol being 
affected by the negative charge present in the polysaccharide chain. As the polysaccharide 
concentration increased more entanglements formed, but after a certain point diffusion coefficient 
no longer reduced and rheological parameters would not be good predictors of diffusivity. Reducing 
droplet size resulted in an improvement in drug release rate, indicating that shear forces within the 
gastrointestinal tract that cause thickened fluid droplets to break up are expected to increase drug 
release.  
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5. Chapter 5.  General discussion and future direction 
5.1 General discussion 
Conditions that affect oral processing, such as dysphagia, are common in the elderly, children and 
adults. Administration of oral dosage forms is usually compromised by weak control in the oral 
cavity which may lead to transportation of medication into the airway. Issues can be minimized by 
using a different formulation that allows administration by an alternative route, which may require 
switching to a different active ingredient, but when these are unavailable patients find other ways to 
take their medicines. A common approach is to crush tablets or open capsules and mix the powder 
with fluid foods (such as jam, apple sauce or yoghurt) or thickened water (prescribed as a water-
replacement for those who are unable to safely swallow thin fluids). Release of a drug from a 
crushed tablet mixed into a thickened fluid is delayed and reduced in a thickener-dependent (Table 
2-5) and drug-dependent manner (Table 2-1). This statement has important implications in 
pharmacotherapy for patients. For example, each year 15 million people worldwide suffer from a 
stroke, 5 million die and another 5 million are left permanently disabled, placing a burden on family 
and community (World Health Organisation, 2015). Warfarin, an anticoagulant drug is used in the 
management of ischaemic stroke. Based on the outcomes of this thesis, it is reasonable to consider 
that the bioavailability of this narrow therapeutic index medication may be compromised if 
administered with thickening agents, and consequently the patient is at risk of not having adequate 
control over their blood clotting. The increasing number of individuals with issues swallowing 
medications is drawing the attention of health professionals to be aware of the patient individual 
needs, health staff to manage medication administration, authorities to regulate best practices to 
follow, and pharmaceutical industry to design new formulations that encompass safe swallowing.   
This thesis presents experimental work conducted to investigate drug release from thickened water. 
The main conclusions from this thesis are presented below, with discussion of future direction that 
the work could take, considered in three areas: issues associated with 1) the polysaccharide 
thickening agent, 2) the drug and dosage form and 3) the techniques used. 
5.1.1 Polysaccharide thickening agent 
Gum-based thickeners have become the most common thickening agents used to manage dysphagia 
due to their stability over time and cost effectiveness (Cichero and Lam, 2014). Whilst descriptive 
labels are commonly used to refer to different thickness levels of liquids used in the management of 
dysphagia, it is more appropriate to objectively measure the viscosity of the thickened liquids. 
Viscosity at 50 s
-1 
is the rheological parameter used to describe the thickness of products prescribed 
for dysphagic patients. However a single value of viscosity is not a good descriptor of the rheology 
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of water (Chapters 2 and 3) or oral liquid formulations (Chapter 3) thickened with polysaccharides 
such as xanthan gum or guar gum, because these are shear thinning viscoelastic fluids for which 
viscosity decreases with increasing shear rate. Complex rheological parameters provided some 
insight; the highest elastic modulus (G’) and apparent yield stress were associated with the greatest 
restriction in drug release (Chapter 3). Additionally, viscosity was not a good indicator of the 
likelihood of limitation in drug release from a crushed tablet incorporated within it. Current 
specifications for thickeners used in dysphagia management will require expanded specifications 
with respect to the viscosity at each level and to include other detailed rheological parameters.  
Investigation of the microstructure of the polysaccharide chains provided new information linking 
material properties and its effect on drug diffusion. Specifically, entanglement of the polysaccharide 
chains dictated the non-Newtonian shear thinning behaviour and drug diffusion of the samples 
investigated (Chapter 4). Diffusion depended on the concentration of the thickener from a critical 
concentration (𝑐*), indicating formation of entanglements (Lapasin and Pricl, 1995), to semidilute 
and concentrated. For guar gum, in the semi-dilute range (0.025% to 0.1%) mechanical spectra 
could not be measured, and these weak entanglements conferred no resistance to drug transfer from 
the polysaccharide solution into SGF through a membrane. For xanthan gum, low modulus values 
(G’ and G”) could be measured for semi-dilute solutions (0.005% to 0.4%), and this was associated 
with a significant reduction in the rate of drug transfer. In the concentrated range, above 0.33% for 
guar gum and 0.8% for xanthan gum, which include all three levels used clinically for dysphagic 
patients (levels 150, 400, 900; Chapter 2), drug transfer was slow but not significantly affected by 
further increases in concentration. 
In order to address difficulties found with the drug diffusion out of the thickened liquids, 
investigations were conducted to determine whether changes in thickened liquid droplet size 
improved drug release. Higher shear rates are required to break up non-Newtonian fluids that 
exhibit shear thinning and viscoelasticity, such as xanthan gum or guar gum solutions in the 
concentrated range, in comparison to that required to break up droplets of a Newtonian fluid such as 
maltodextrin. Maintenance of a single large mass was observed to occur for water thickened with a 
variety of commercial products, particularly at greater thicknesses (Chapter 2) and formulations 
with higher apparent yield stress values, i.e. requirement for a higher shear stress to break the 
structure and cause it to flow, exhibited the slowest dissolution profiles (Chapter 3). Reducing the 
single mass into multiple small droplets resulted in faster and greater drug release (Chapter 4), 
indicating that shear forces within the gastrointestinal tract that cause thickened fluid droplets to 
break up are expected to increase drug release.  
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This thesis has investigated properties of polysaccharides used in commercial thickening products 
designed for use by dysphagic patients. The development of an ideal thickening agent, which retains 
suitable rheological parameters to ensure safe swallowing by dysphagics but also allows immediate 
drug release in the stomach, could be the future direction for research and a range of options are 
described below.  
a) Particulate systems such as starch release small molecules faster than polymeric systems such as 
xanthan gum, which was proposed to be applicable in taste and flavour perception of foods 
(Williams et al. 2008). Commercial thickeners that contain starch allow faster drug release than 
xanthan gum thickeners when used at the same level of thickness defined by the manufacturers 
(Chapter 2), however viscosity at 50 s
-1
 of the products was not comparable and so further work 
would be needed to compare drug release from equiviscous solutions. Additionally, starch-
based products continue to thicken on standing and so viscosity is time-dependent, which is a 
safety concern that would need to be considered. 
b) Alterations to polysaccharides, such as extrusion, change rheological parameters and so may be 
expected to have an effect on drug release. Extruded xanthan gum behaves more like starch, i.e. 
as a particle rather than a polymer. The polymer chain network forms within individual particles 
that swell and disperse in the solvent but the normal rigid-rod-like structure is not fully 
produced (Foster and Mitchell, 2012).  
c) Rheological properties can be altered by combining gums such as xanthan gum with 
galactomanans such as guar gum and locust bean gum (Pinheiro et al., 2011). This could 
potentially improve drug release as a result of different responses to shearing in the release 
media. 
d) A pH-responsive polymer system that would be a semi-solid fluid at the neutral or slightly 
acidic pH typical of the mouth, and become liquid at the lower pH of the stomach would be 
ideal. pH-sensitivity is primarily due to the presence of the alteration of structure resulting from 
change in ionization status of charged groups on biopolymers such as alginic acid, chitosan or 
synthetic polymers such as carbomer.  
e) Thermal sensitivity is an alternative characteristic to consider. A carboxymethyl derivative of 
scleroglucan has thermosensitive properties and exhibits a gel-sol transition between 30-40°C, 
dependent on the concentration of mixture with CaCl2 added, and drug release from the polymer 
was temperature dependent (Feeney et al., 2009). This shows that polymers with a thermal 
transition at a temperature just below 37°C may be possible to achieve, such that the polymer 
remains semi-solid when placed in the mouth and disperses on reaching 37°C. 
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f) Microstructural changes resulting in breakdown of the gel structure may be an approach for 
thickener design. For example, a binary aqueous mixture of xanthan gum and anionic 
polysaccharides (i.e. alginate, polyacrylate, carboxymethylcellulose, i-carrageenan, and low 
methoxyl pectin) results in segregative phase separation. This occurs as a consequence of the 
repulsive interactions between polyelectrolytes, forming liquid crystalline structures in the 
xanthan-rich domain and resulting in decreased modulus G’ and G” values (Boyd et al., 2009). 
This approach was investigated to be utilised as polysaccharide mucosal protective coating in 
gastrointestinal reflux. Oral drug delivery with thickened fluids requires the breakdown of the 
structure at stomach level to guarantee complete delivery. However, in the context of oral drug 
delivery the point at which structural breakdown would occur is not clear. 
g) The use of an excipient food (McClements and Xiao, 2014) that has appropriate rheology but 
improves oral bioavailability of drug compounds may be an alternative approach. For example, 
yoghurt, a structured fluid, may be appropriate in terms of drug release and rheology, depending 
on the severity of the dysphagia (Manrique et al. 2014). The use of foods such as yoghurt 
requires further consideration of product components (i.e. starch, gums, gelatin etc) in terms of 
rheology and drug interactions that could affect drug bioavailability. Potential solubilization of 
the low solubility active ingredient could be improved in the presence of yoghurt for instance.  
5.1.2 Drug and dosage form 
The current study demonstrated that release of the drug from thickened fluid was due to delayed 
diffusion of drug molecules, not to delay in dissolution of the drug powder within the 
polysaccharide matrix. This was shown with paracetamol in Chapter 3, where the rate of release 
was not improved by pre-dissolving paracetamol (i.e. thickening the dissolved effervescent tablet or 
elixir, or mixing crushed drug with water prior to adding thickener powder) in comparison to using 
dispersed drug powder (i.e. thickening the suspension, or adding crushed drug to pre-thickened 
water). This was supported in Chapter 4 with atenolol, for which solubility of atenolol was higher in 
2.2% xanthan gum than in water but the diffusion coefficient was one order of magnitude lower in 
2.2% xanthan gum than water. Note, however, that both drugs used in this study were selected to 
ensure that they would be soluble in the dissolution test environment: atenolol is a BCS class III 
drug (high solubility/low permeability) and paracetamol is a borderline I/III (high 
solubility/intermediate permeability). Other drug molecules may not respond in the same manner, 
and investigations using different acid/base properties (i.e charged at the pH condition of the 
experiment) or different drug classification for which low solubility is an issue (i.e BCS class II) 
will provide further insights into drug release from gum-based thickened water.  
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There was preliminary evidence for an interaction between the positive charge on the weakly basic 
atenolol (pKa 9.3) and the negative charge on the weakly acidic xanthan gum (estimated pKa 4.5; 
(Bueno and Petri, 2014), both of which would be ionized at the pH of the water (pH 5.2) used with 
the thickener. At semi-dilute gum concentrations, diffusion of atenolol was slowed when mixed into 
xanthan gum but not guar gum, and mechanical spectra were measured for xanthan gum but not 
guar gum indicating stronger polymer entanglement for the former (Chapter 4). This effect on 
diffusion was noted even though the xanthan gum product used contained 1 g/100 g sodium, which 
would be expected to also interact with xanthan gum’s ionized groups. To investigate drug-gum 
charge interactions further, comparison could be made of xanthan gum solutions prepared to control 
ionization status (e.g. using water at pH 2 vs pH 7), or pure xanthan gum with variable 
concentrations of electrolyte, or different drugs that vary in ionization status, along with a technique 
such as FTIR or NMR to measure differences in interactions between the drug and polymer. 
The excipients contained in the drug formulations are an additional factor to consider as a cause of 
some of the drug-dependent variation in release from thickened water. In liquid medications, 
excipients added to control drug sedimentation and resuspension affected viscosity when thickener 
was added, causing much higher viscosity (and reduced drug release) than when the same quantity 
of thickener was added to water (Chapter 3). For crushed tablets, movement of atenolol in 2.2% 
xanthan gum into SGF was slower than the same concentration of pure atenolol powder (Chapter 4). 
The mechanism by which excipients from formulations modify dissolution has not been assessed; it 
may be due to direct and specific interactions between the polysaccharide and excipients, or may 
simply be a steric impediment to drug movement caused by insoluble fillers and binders. Future 
work could investigate the effect of individual excipients commonly used in tablet formulations 
(Vogelpoel et al., 2004) on diffusion and release of drugs from thickened water. For example, 
comparison of soluble (e.g. lactose) and insoluble (e.g. talc, silica) excipients, and the role of 
viscosity-altering agents (e.g. starch, gelatin) could be investigated. 
5.1.3 Techniques used 
 Dissolution 
The in vitro dissolution test performed under specific conditions can be used as a prognostic tool for 
evaluating the bioavailability of certain drugs (Amidon et al., 1995). However, clearly, there are 
limitations to the conclusions that can be drawn when a simple dissolution environment is used. 
This is particularly the case for a semi-solid mass for which droplet size is important in determining 
drug release (Chapter 4) because any difference in mixing and shear rate would be expected to alter 
release. 
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Drug release and absorption could be assessed in a more physiologically-relevant environment. The 
dynamic gastric model (DGM) consists of three compartments that are intended to mimic the main 
mechanical and chemical functions of the stomach including mixing, shear rates and forces, 
peristalsis and gastric emptying (Wickham et al., 2009). The fed stomach model (FSM) is another 
attempt to be representing the stomach by using the standard pharmacopoeial dissolution apparatus 
with a linked flow-through vessel hosting the tested medication. The fluid dynamics are computer-
controlled and simulate the exposure pressures of in vivo conditions (Koziolek et al., 2014). The 
TNO gastrointestinal model (TIM-1) is a multi-compartment model that is intended to simulate the 
physiological conditions of the stomach through to the small intestine including the dynamics of 
mixing, gastric emptying and intestinal transit times (Minekus et al., 1999). It also mimics gastric 
and duodenum fluid composition, secretion, and body temperature. Using apparatus such as this 
may allow exploration of the effects of gastrointestinal forces and motility, in the presence and 
absence of food, on polymer disintegration and drug release.  
Computer-based simulation is an alternative approach that could be taken to consider the complex 
dynamics of the gastrointestinal tract. A 3-D model of the shape and motility of the stomach, 
generated using computational fluid dynamics was used to characterise fluid dynamics of gastric 
contents at different viscosities (Ferrua et al., 2011). This would potentially show the stomach 
peristaltic movement that generates squeezing, crushing and impact on food, and therefore inform 
as to the pressures and shear that may be expected to occur within the stomach environment in the 
presence of food. 
While these in silico approaches would increase understanding of drug release in the 
gastrointestinal tract before absorption occurs, they all require some real in vivo data for 
comparison. Ideally, in vivo testing should be addressed promptly due to the implications in drug 
delivery detailed here. There is evidence that absorption of whole digoxin, penicillin and metformin 
tablets may be reduced when consumed with guar gum as a source of dietary fibre (Huupponen et 
al., 1984, Gin et al., 1989), but the effect of mixing crushed tablets into thickened fluids on drug 
absorption has not been addressed.  
 Diffusion 
The vertical diffusion cell (VDC, Franz cell, transdermal delivery system) is a simple, reliable and 
reproducible means of measuring drug release from semi-solid (cream, ointment, gel) dosage forms 
(United States Pharmacopoeia, 2009). On the positive side, VDC can test claims around dosage 
forms that otherwise could not be assessed with standard dissolution settings and provides insights 
on drug release from a mechanistic point of view. On the negative side, some operational aspects 
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may affect reproducibility, such as the instrument dimensions, rotational speed and sampling times 
used (Ng et al., 2010). The value of using automatic apparatus, rather than traditional Franz cells, 
was demonstrated by verifying test temperature, speed requirements and sampling procedure, which 
consequently minimises variability in results (Lucero et al., 2013). One particular issue that was 
apparent during the present study is the presence of bubbles in the receptor cell, which affect the 
transfer of drug from the donor chamber. While 3 bubbles per 1 mm are permitted (United States 
Pharmacopoeia, 2009), adequate training is required to ensure that bubbles are  removed from the 
receptor chamber during the test by tilting the cells once, and care was taken to avoid introducing 
new bubbles during sampling and replenishment of the media. A consistent experimental procedure 
will minimise % RSD, which therefore estimates the overall performance of the operator. A second 
important issue is the time required to reach the equilibrium, which in this research was between 12 
to 13 minutes from the start of the experiment (calculated by extrapolating the linear regression line 
along the time axis, Figure 4-2), prior to which samples should not be taken from the receptor cell. 
Finally, application of the Higuchi diffusional model (Equation 4-2) to the results from the VDC 
experiment requires that the amount of the drug being loaded should be at least 10 times the 
concentration solubility in order to maintain sink conditions (Siepmann and Peppas, 2011), the 
amount and distribution of sample placed into the donor cell should be uniform, and agitation 
should be sufficient to avoid biopolymer sublayer formation without vortex formation (Tharakan, 
2009).  
 Rheology  
Rheological measurements are subject to error between replicates, with 10% error being commonly 
acceptable for viscosity and in this thesis average measurements of viscosity were within 10% of 
experimental error. For some low viscosity fluids, G’ (storage modulus) was unmeasurable, i.e. 
outside of the measurement range, and may not mean that the fluid does not have a G’, so consistent 
methodology and replication is essential to check these results. For any rheological measurement, 
under-filling of the sample between plates of the rheometer can cause significant errors; instead 
over-filling and appropriate trimming of the fluid leads to more consistent results. To avoid 
evaporation of the sample during the testing, which can be up to 30 minutes long at 37°C, a low 
viscosity fluid (silicone oil) covered the edge of the sample. Certain errors resulting from the nature 
of the sample, for instance particle settling during the steady shear and oscillation tests resulting in 
secondary flow or slip (Davies and Stokes, 2008) may cease if a different geometry (e.g rough 
surface, vane tool) is used. Parallel plate or vane tool geometries were extensively used in this 
thesis, and in some circumstances cone and plate was used for low viscosity fluids but not for 
suspensions as particles can deposit in the gap and cause errors (Stokes and Telford, 2004). Finally, 
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internal rheometer calibration is essential to check air bearing and heating are correct, and in this 
thesis calibration was conducted daily.  
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6. Appendices  
6.1 Appendix A. Mathematical models used to assess drug release 
6.1.1 Similarity factor (𝒇𝟐) 
The similarity factor (𝑓2) is a logarithmic transformation of the sum-squared error of differences 
between the test 𝑇𝑗 and reference products 𝑅𝑗 over all time points. It is used within the 
pharmaceutical industry and adopted by the FDA and the EMEA as a criteria for the assessment of 
the similarity between two in vitro dissolution profiles. For example, it is commonly used as part of 
an assessment of bioequivalence of a test product to a reference product. Two profiles are declared 
to be similar if 𝑓2 is between 50 and 100 (Costa and Sousa Lobo, 2001). 
Equation 6-1 
𝑓2 = 50 log {[1 + (
1
𝑛
) ∑ 𝑊𝑗 |𝑅𝑗𝑇𝑗|
2
𝑛
𝑖=1
]
−0.5
𝑥 100} 
 
 
6.1.2 Korsmeyer-Peppas model (power law model) 
This power law model came into use after the study of the mechanism of solute release from 
porous-swellable release systems (Korsmeyer et al., 1983). Based on the experimental results, drug 
release is explained by the mathematical expression:  
Equation 6-2 𝑀𝑡
𝑀∞
= 𝑘𝑡𝑛 
where 𝑀𝑡 is the amount of drug release at time (𝑡), 𝑀∞ is the total drug released over the duration 
of the experiment, 𝑘 is the kinetic constant, and 𝑛 is the release exponent. This expression 
establishes that release follows an exponential order and that the rate of release decreases as the 
concentration of the drug molecule diminishes. The importance of the release exponent 𝑛 lies in 
their contribution to the knowledge of the transport mechanism of drug molecules in solid matrices.  
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Table 6-1. Release exponents and drug transport mechanism in polymeric systems from (Korsmeyer 
et al., 1983) 
Release exponent (𝒏) Drug transport mechanism Rate as a function of time 
0.5 Fickian diffusion 𝑡−0.5 
0.5<𝑛<1.0 Anomalous transport 𝑡𝑛−1 
1.0 Case II transport Zero order release 
Higher than 1.0 Super Case II-transport 𝑡𝑛−1 
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6.2 Appendix B. Matlab predictions of the 𝑴𝒕/𝑴𝒊𝒏𝒇 with the data entry as a text output 
from the model. 
6.2.1 0.5 cm radius  
clear all 
close all 
B=importdata('experimental.txt','\t',1); 
savename='Results'; 
B=B.data; 
t=B(:,1); 
y=B(:,2); 
nt=length(t); 
Mt_Minf=zeros(nt,1); 
  
D=6.5e-11;        %Diffusivity (m^2/s) 
Cs=30.3;        %Cs 
Cini=6.67;      %Cini 
R=0.5;         %particle radius (cm) 
  
Cs_Cini=Cs/Cini; 
R=0.01*R; 
  
factor=-3*Cs_Cini*D/R^2; 
Mx=[0:1e-5:0.9999]; 
tx=(Mx-1.5*(1-(1-Mx).^(2/3)))/factor; 
  
%CALCULATED VALUES 
for i=1:nt 
    Mt_Minf(i)=interp1(tx,Mx,t(i)); 
end 
  
BB(1,1:2)={'  time(s)  ','  Mt/Minf  '}; 
for i=2:nt+1 
    BB(i,1:2)={t(i-1),Mt_Minf(i-1)}; 
end    
xlswrite(savename,BB,1) 
  
%FITTING 
yy=y-1.5*(1-(1-y).^(2/3)); 
fun=@(a,x) a*x; 
  
x0=-3*D/R^2*Cs_Cini; 
m=lsqcurvefit(fun,x0,t,yy); 
  
AA(1,1:2)={'  measured slope  ','  fitted slope  '}; 
AA(1,1:2)={x0,m}; 
xlswrite(savename,AA,2) 
plot(t,yy,'or',t,m*t,'b',t,x0*t,'g') 
legend('experimental','fitted','estimated') 
disp('estimated=') 
disp(x0) 
disp('fitted=') 
disp(m)  
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6.2.2 0.84 cm radius 
lear all 
close all 
B=importdata('experimental.txt','\t',1); 
savename='Results'; 
B=B.data; 
t=B(:,1); 
y=B(:,2); 
nt=length(t); 
Mt_Minf=zeros(nt,1); 
  
D=6.5e-11;        %Diffusivity (m^2/s) 
Cs=30.3;        %Cs 
Cini=6.67;      %Cini 
R=0.84;         %particle radius (cm) 
  
Cs_Cini=Cs/Cini; 
R=0.01*R; 
  
factor=-3*Cs_Cini*D/R^2; 
Mx=[0:1e-5:0.9999]; 
tx=(Mx-1.5*(1-(1-Mx).^(2/3)))/factor; 
  
%CALCULATED VALUES 
for i=1:nt 
    Mt_Minf(i)=interp1(tx,Mx,t(i)); 
end 
  
BB(1,1:2)={'  time(s)  ','  Mt/Minf  '}; 
for i=2:nt+1 
    BB(i,1:2)={t(i-1),Mt_Minf(i-1)}; 
end    
xlswrite(savename,BB,1) 
  
%FITTING 
yy=y-1.5*(1-(1-y).^(2/3)); 
fun=@(a,x) a*x; 
  
x0=-3*D/R^2*Cs_Cini; 
m=lsqcurvefit(fun,x0,t,yy); 
  
AA(1,1:2)={'  measured slope  ','  fitted slope  '}; 
AA(1,1:2)={x0,m}; 
xlswrite(savename,AA,2) 
plot(t,yy,'or',t,m*t,'b',t,x0*t,'g') 
legend('experimental','fitted','estimated') 
disp('estimated=') 
disp(x0) 
disp('fitted=') 
disp(m)  
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6.2.3 1.0 cm radius 
clear all 
close all 
B=importdata('experimental.txt','\t',1); 
savename='Results'; 
B=B.data; 
t=B(:,1); 
y=B(:,2); 
nt=length(t); 
Mt_Minf=zeros(nt,1); 
  
D=6.5e-11;        %Diffusivity (m^2/s) 
Cs=30.3;        %Cs 
Cini=6.67;      %Cini 
R=1.0;         %particle radius (cm) 
  
Cs_Cini=Cs/Cini; 
R=0.01*R; 
  
factor=-3*Cs_Cini*D/R^2; 
Mx=[0:1e-5:0.9999]; 
tx=(Mx-1.5*(1-(1-Mx).^(2/3)))/factor; 
  
%CALCULATED VALUES 
for i=1:nt 
    Mt_Minf(i)=interp1(tx,Mx,t(i)); 
end 
  
BB(1,1:2)={'  time(s)  ','  Mt/Minf  '}; 
for i=2:nt+1 
    BB(i,1:2)={t(i-1),Mt_Minf(i-1)}; 
end    
xlswrite(savename,BB,1) 
  
%FITTING 
yy=y-1.5*(1-(1-y).^(2/3)); 
fun=@(a,x) a*x; 
  
x0=-3*D/R^2*Cs_Cini; 
m=lsqcurvefit(fun,x0,t,yy); 
  
AA(1,1:2)={'  measured slope  ','  fitted slope  '}; 
AA(1,1:2)={x0,m}; 
xlswrite(savename,AA,2) 
plot(t,yy,'or',t,m*t,'b',t,x0*t,'g') 
legend('experimental','fitted','estimated') 
disp('estimated=') 
disp(x0) 
disp('fitted=') 
disp(m) 
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6.2.4 1.53 cm radius 
 
clear all 
close all 
B=importdata('experimental.txt','\t',1); 
savename='Results'; 
B=B.data; 
t=B(:,1); 
y=B(:,2); 
nt=length(t); 
Mt_Minf=zeros(nt,1); 
  
D=6.5e-11;        %Diffusivity (m^2/s) 
Cs=30.3;        %Cs 
Cini=6.67;      %Cini 
R=1.53;         %particle radius (cm) 
  
Cs_Cini=Cs/Cini; 
R=0.01*R; 
  
factor=-3*Cs_Cini*D/R^2; 
Mx=[0:1e-5:0.9999]; 
tx=(Mx-1.5*(1-(1-Mx).^(2/3)))/factor; 
  
%CALCULATED VALUES 
for i=1:nt 
    Mt_Minf(i)=interp1(tx,Mx,t(i)); 
end 
  
BB(1,1:2)={'  time(s)  ','  Mt/Minf  '}; 
for i=2:nt+1 
    BB(i,1:2)={t(i-1),Mt_Minf(i-1)}; 
end    
xlswrite(savename,BB,1) 
  
%FITTING 
yy=y-1.5*(1-(1-y).^(2/3)); 
fun=@(a,x) a*x; 
  
x0=-3*D/R^2*Cs_Cini; 
m=lsqcurvefit(fun,x0,t,yy); 
  
AA(1,1:2)={'  measured slope  ','  fitted slope  '}; 
AA(1,1:2)={x0,m}; 
xlswrite(savename,AA,2) 
plot(t,yy,'or',t,m*t,'b',t,x0*t,'g') 
legend('experimental','fitted','estimated') 
disp('estimated=') 
disp(x0) 
disp('fitted=') 
disp(m)  
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6.3 Analytical methodology validation  
A description of the basic principles of the analytical testing to quantify atenolol and paracetamol in 
samples of the active ingredient in powder, elixir, suspension, effervescent tablets, tablets, crushed 
tablets and crushed tablets mixed with thickened water. A validation guideline was followed  
(International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use, 1996)  
 Apparatus/Equipment  
A standard spectrophotometer UV-VIS Hitachi U-1900 ratio beam was used for wavelength scan 
measurements (400 nm to 200 nm) and for single wavelength measurements. Quartz cuvettes with 1 
cm path length, 3 mL capacity, were used through all experiments. 
 Reagents and standards: 
Atenolol (CAS 29122-68-7) PCCA, South Wilcrest Houston, Texas 77099 and Paracetamol 
(acetaminophen) USP powder, lot C148621 (CAS 103-90-2), both qualified in house reference 
material (100% purity). 
Hydrochloric acid (37% w/v) analytical reagent (Merck, Bayswater, Vic, Australia), Milli Q 
Gradient A-10 water purification system (18.2 Ωs/cm, 20°C) from Millipore (Bayswater, Vic, 
Australia) and filters: Nylon membranes 25 mm (Grace Discovery Sciences, Vic, Australia) with 
Swinex® filter holder (Millipore, Bayswater, Vic, Australia). 
6.3.1 Atenolol 
Atenolol stock solution: Approximately 125 mg of atenolol in house reference material (100% 
purity) was weighed and dissolved in SGF solution pH 1.2 ± 0.1 at 25°C. Samples were sonicated 
for 5 minutes and filled up to 250 mL to obtain a concentration of 500 μg/mL in triplicate.  
a) Specificity/selectivity 
Wavelength scans from 200 nm to 400 nm were obtained for blank (SGF solution), blank + xanthan 
gum, blank + guar gum and blank + maltodextrin used in concentration levels likely to be found in 
solution. No interfering peaks were present (Figure 6-1). 
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Figure 6-1. Absorbance of guar gum 1.4% with and without atenolol, both in SGF. A blank of SGF 
pH 1.2 was used.  
b) Linearity 
A total of 10 concentration levels were prepared 5-120 μg/mL by diluting corresponding volumes of 
the filtrated stock solution and fill up to 5 mL. Volumes were taken using calibrated automatic 
pipettes.  
Linear relationship across the range of concentration from 5-120 μg/mL was obtained at the 
maximum absorbance wavelength of 274 nm (Figure 6-2). The correlation coefficient, 𝑦-intercept, 
slope of the regression line and residual sum of the squares indicate that calibration model is valid 
(𝑦 = 0.0043𝑥 –  0.0073, 𝑟2 = 0.999). 
c) Intermediate precision 
For the long term variability of the measurement process comparisons were made for the method 
run. No difference between atenolol solutions measured in different instruments/days/solutions was 
found. Differences between slopes are not significant and pooled slope equals 0.0043 and meets 
95% confidence interval for slope with 𝑟2 of 0.9999. Repeatability was measured over six replicates 
at 5 and 120 μg/mL Table 6-2. 
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Figure 6-2. Replicate standard curves for atenolol in the range 5 – 120 µg/mL. 
Table 6-2. Validity of calibration model y = ax + b for atenolol solutions in SGF. 
Concentrations  5 μg/mL 120 μg/mL 
Standard deviation (SD) 0.0004082 0.001549 
Standard error of mean  0.0001667 0.0006325 
Coefficient of variation (%RSD) 1.87% (≤ 2%) 0.27% (≤ 2%) 
Confidence interval  0.02140 -0.02226 0.5684- 0.5716 
 
d) Lower detection and quantitation limit 
The limit of detection (LOD = 1.13 mcg/mL) and limit of quantification (LOQ = 3.41 mcg/mL) 
were determined using the residual standard deviation of the regression line (σ) and slope (S) of the 
calibration curve for each alkaloid standard with LOD being 3.3σ/S and LOQ 10σ/S.  
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6.3.2 Paracetamol 
Paracetamol stock solution: 100 mg of paracetamol USP powder was weighed and dissolved 
carefully with SGF solution pH 1.2 ±0.1 at 25°C. Samples were sonicated for 5 minutes and filled 
up to 100 mL to obtain concentration 100 μg/mL. Corresponding dilutions of stock solutions were 
prepared for calibration and other validation characteristics in triplicates.  
a) Specificity/selectivity 
Wavelength scans from 200 nm to 400 nm were obtained for blank (SGF solution), blank + 
Easythick, and the blank in the presence of elixir, suspension, crushed and effervescent tablets used 
in concentration levels likely to be found in solution. No interfering peaks were present Figure 6-3)  
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Figure 6-3. Absorbance of paracetamol suspension in the presence SGF pH 1.2 with SGF used as a 
blank in the UV spectrum.  
b) Linearity 
Concentration levels from were prepared in the range 2 to 10 μg/mL by diluting corresponding 
volumes of the filtrated stock solution and filled up to 5 mL. 
A linear relationship across the range of concentration from 2-10 μg/mL was obtained at maximum 
absorbance wavelength of 244 nm (Figure 6-4). The correlation coefficient, 𝑦-intercept, slope of the 
regression line and residual sum of the squares indicated that calibration model is valid (𝑦 
=0.0663𝑥 + 0.0083, 𝑟2=0.998). 
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Figure 6-4. Replicate standard curves for atenolol in the range 5 – 120 µg/mL. 
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